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Pretargeted nuclear imaging and radiotherapy have recently attracted increasing attention for diagnosis
and treatment of cancer with nanomedicines. This is because it conceptually offers better imaging
contrast and therapeutic efﬁciency while reducing the dose to radiosensitive tissues compared to con-
ventional strategies. In conventional imaging and radiotherapy, a directly radiolabeled nano-sized vector
is administered and allowed to accumulate in the tumor, typically on a timescale of several days. In
contrast, pretargeting is based on a two-step approach. First, a tumor-accumulating vector carrying a tag
is administered followed by injection of a fast clearing radiolabeled agent that rapidly recognizes the tag
of the tumor-bound vector in vivo. Therefore, pretargeting circumvents the use of long-lived radionu-
clides that is a necessity for sufﬁcient tumor accumulation and target-to-background ratios using con-
ventional approaches.
In this review, we give an overview of recent advances in pretargeted imaging strategies. We will
critically reﬂect on the advantages and disadvantages of current state-of-the-art conventional imaging
approaches and compare them to pretargeted strategies. We will discuss the pretargeted imaging
concept and the involved chemistry. Finally, we will discuss the steps forward in respect to clinical
translation, and how pretargeted strategies could be applied to improve state-of-the-art radiotherapeutic
approaches.
© 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
1.1. Nanomedicines in modern medicine
The emergence of nanomedicines for use in the treatment of
cancer has been rapidly increasing over the past decades since their
application has great potential to improve current cancer diagnosis
and therapy. In general, a wide range of materials ranging from
inorganic particles to proteins and organic structures such as
polymers and liposomes can be used as nanomedicines. In this
review, nanomedicines are deﬁned as nano-sized targeting vectors
that accumulate via passive targeting into tumors (Fig. 1) [1,2]. The
mode of action for these nanomedicines can vary widely. Some
nanomedicines have been designed to act as therapeuticsnhagen, Denmark.
Herth).
Ltd. This is an open access article uthemselves, e.g. as thermal agents in photothermal therapy [3,4],
others have been developed to be used as drug carriers [5e7]. These
carriers have great promise in delivering and releasing chemo-
therapeutics more selectively to tumors [5,6,8]. For example, lipo-
somal encapsulated chemotherapeutic drug formulations (e.g.
Doxil (liposomal doxorubicin), MM-302 (HER2 antibody-targeted
liposomal doxorubicin) or MM-398 (nanoliposomal irinotecan)
are three examples of such delivery systems [9e11].
1.2. The enhanced permeability and retention effect
The enhanced permeability and retention (EPR) effect is
responsible for the passive accumulation of nanomedicines into
tumor tissue [12]. The effect is a result of the rapid and abnormal
growth of tumor blood vessels, which leads to increased fenestra-
tions between cells and poor lymphatic drainage. These circum-
stances enable nanomedicines to extravasate from the blood pool
into the tumor tissue and being retained there (Fig. 1B) [13e15].nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. (A) Schematic illustration of different types of nanomedicines used in modern medicine. The inorganic nanoparticle and liposome is shown with a poly (ethylene glycol)
(PEG) layer that is used in vivo to increase circulation time. (B) The EPR effect: Leaky vasculature and impaired lymphatic drainage allows nanomedicines in the blood to extravasate
into the tumor microenvironment.
1 In comparison, monoclonal antibodies typically show ID/kg around the same
magnitude as nanomedicines do (0.001%e0.01% of the injected dose per gram of
tumor [Goldenberg, D. M., Cancer imaging with radiolabeled antibodies, Kluwer
Academic Pubslishers 1990, ISBN: 978-0-7923-0631-3] [Scott et al., Nat Rev Cancer,
2012, 12:278e87] [Marcucci F. et al., MAbs, 2013, 5: 34e46].
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likelihood of tumor accumulation via the EPR effect, simply because
more nanomedicines pass through the leaky tumor vasculature
over time.
Tumor accumulation via EPR is, among other things, dependent
on the physicochemical characteristics of the nanomedicine itself.
In particular the size, surface properties, shape and charge can alter
accumulation [5,16]. Besides matching the gap sizes of the leaky
tumor vessels, the dimensions of the nanomedicine should also be
such that early clearance from the blood is avoided [17,18]. To
prevent renal excretion, nanomedicines should typically be larger
than ~6 nm. On the other hand, nanomedicines larger than
~200 nm are rapidly recognized and sequestered by the reticulo-
endothelial system (RES) (mainly consisting of the liver and the
spleen). Furthermore, the surface of the nanomedicine has also an
inﬂuence on RES recognition. Neutrally charged nanomedicines
tend to be better shielded from recognition and therefore have
longer circulation times. A common strategy to prevent RES
recognition of nanomedicines is shielding them from RES-
facilitating proteins (opsonins) by decorating the surface with
neutralizing molecules such as poly(ethylene glycol) (PEG) [17].
The tumor microenvironment can also affect the accumulation
of passively targeting nanomedicines [8,19]. For example, the
vascular density is commonly unevenly distributed throughout
solid tumors with the highest abundance in the periphery at the
host interface and lowest in hypoxic and adjacent necrotic regions.
Abnormal vessel structure causes irregular blood ﬂow within tu-
mors and impaired lymphatic drainage can lead to high interstitial
pressure gradients in the tumor microenvironment. Moreover, the
gap sizes in the vessel walls are commonly heterogeneous
distributed throughout the tumor [15,20]. Therefore, it is not sur-
prising that the EPR effect is strongly affected by the tumor
microenvironment and consequently, the accumulation of
passively targeting nanomedicines is variable.
So far, no clear relationship between tumor type, size or stage
and EPR has been established neither in animal models nor in
cancer patients [21e23]. In fact, considerable variations in tumor
uptake of radiolabeled liposomes between different tumor types
and even between patients with the same tumor type have been
observed [9,10,24].
1.3. Personalized medicine
Personalized medicine, where medical decisions, practices, and/
or products are being tailored to the individual patient, is a concept
based on the application of companion diagnostics. It is used to
identify which patients will likely beneﬁt from a particular therapy,
or conversely and often as important, which patients are likely non-responders and should receive a different treatment strategy
(Fig. 2A).
In general, patient to patient variations in EPR-mediated tumor
uptake represents a challenge for the overall application of
passively accumulating nanomedicines. However, accumulation of
up to 50% injected dose per kg (ID/kg) has been observed in pa-
tients1 [24] and as such, the application of nanomedicines is still
promising for clinical use. Therefore, screening methods with the
ability to select patients that would beneﬁt from EPR based treat-
ment strategies would be of great value. Diagnostic imaging with
Positron Emission Tomography (PET) or Single Photon Emission
Computed Tomography (SPECT) are routinely used in the clinic for
identiﬁcation of patient cohorts and monitoring of treatment
response [25,26]. This is because PET and SPECT are highly sensitive
(the level of detection approaches 1012M of tracer) and offer
isotropism (i.e. ability to detect organ accumulation accurately,
regardless of tissue depth) [27]. Furthermore, with PET, it is
possible to get a quantitative measure for the amount of nano-
medicine delivered to the tumor, making this modality especially
suited for personalized medicine [28].
In 2017, Lee and colleagues published the ﬁrst PET study quan-
tifying the variability of the EPR-mediated accumulation of nano-
medicines in relation to the treatment response in patients with
metastatic breast cancer [9]. In this study, the treatment response
of human epidermal growth factor 2 (HER2)-targeted liposomal
doxorubicin (MM-302) correlated positively with the extent of EPR-
mediated uptake of 64Cu-MM-302 (Fig. 2B). Similarly, Perez-
Medina et al. reported a correlation between uptake of a89Zr-
labeled PEGylated liposome and the effect of Doxil, liposome
encapsulated doxorubicin, on tumor growth in a xenograft model
of breast cancer [29,30].1.4. Imaging of nanomedicines during the drug development
process
Considering the increa amount of knowledge in the area of drug
delivery and the number of novel nanomedicines that are contin-
uously being developed, only a few compounds make it into clinical
trials. In fact, in a recent publication surveying the literature from
2005 until 2015, it was found that there has been no improvement
in the median accumulation of nanomedicines within this time
Fig. 2. Personalized medicine. (A) As a general principle, patients are prescreened, e.g. using PET imaging, prior to therapy with a radiolabeled version of the nanomedicine
formulation (selection step). This allows identifying individuals showing sufﬁciently high target accumulation that are more likely to respond to treatment with the nanomedicine
formulation whereas patients with low target accumulation should receive or be changed to an alternative treatment strategy. (B) Correlation between EPR effect and treatment:
64Cu-MM-302 deposition uptake lesions are shown for individual patients. A threshold was selected to divide patients into "low uptake" patients and "high uptake" (left). Median
progression-free survival (PFS) of the patients is shown. "High uptake" patients have a higher probability to be sensitive to treatment with MM-302 (right). The accumulation proﬁle
of MM-302 is independent of the targeting ligand, hence dictated primarily by the EPR effect. Figure modiﬁed from Ref. [9].
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leagues identiﬁed several pitfalls that could lead to the observed
statistics: I) overinterpretation of the EPR effect, II) poor tumor and
tissue penetration of nanomedicines, III) misunderstanding of the
potential usefulness of active drug targeting, IV) irrational formu-
lation design, V) lack of proper animal models, which are physio-
logically more relevant and predictive for the clinical situation,2
and VI) insufﬁcient integration of non-invasive imaging tech-
niques [5].
The possibility to use nuclear imaging techniques to quantify the
EPR effect on an individual basis and thereby select patient groups
likely to respond to nanomedicines has been discussed in the
previous section (see 1.3, Personalizedmedicine). However, nuclear
imaging techniques can also be used during drug development. It
can be applied to study the biodistribution of nanomedicines, to
quantify drug release, to ﬁnd the optimal dose within clinical trials
and to assess the therapeutic efﬁcacy in real-time [5,29,32]. For
instance, nuclear imaging has been used to study the circulation2 The EPR effect is generally rather high in most small animal tumor models
compared to patient tumors. This leads to discrepancies in efﬁcacy between pre-
clinical and clinical trials [Shi J et al., Nat. Rev. Cancer, 2017, 17: 20e37] [Lammers T
et al., J Control Release, 2012, 161: 175e187].time of liposomes and to identify which liposome has the highest
potential to be used for passive drug delivery [24]. In vivo bio-
distribution studies can also efﬁciently show if the respective
nanomedicine is being deposited in tissues that could result in
toxicological concerns. A prominent example, which shows that
nuclear imaging should be included early in nanomedicine drug
development, is the study published by Seymour and colleagues
[33]. They studied the biodistribution of N-(2-Hydroxypropyl)
methacrylamide (HPMA) copolymer-bound doxorubicin (PK2) in
31 patients with primary or metastatic liver cancer. In phase I/II
clinical trials, they found that the treatment efﬁcacy was low.
Detailed imaging analysis revealed retrospectively that PK2 targets
healthy liver tissue rather than the tumor. Earlier implementation
of this study could have prevented expensive phase I/II trials.
2. State of the art labeling strategies for non-targeted
nanomedicinal drug delivery systems
2.1. Pharmacokinetics of nanomedicines and the choice of
radionuclide for imaging
In order to conduct PET or SPECT imaging of long-circulating
nanomedicines, suitable radionuclides have to be attached to the
corresponding structure (see section 2.2). Table 1 summarizes key
E.J.L. Steen et al. / Biomaterials 179 (2018) 209e245212properties of radionuclides used for PET and SPECT imaging. The
most commonly used PET and SPECT radionuclides such as carbon-
11 (20.4min), ﬂuorine-18 (110min) and technetium-99m (6.01 h)
have rather short half-lives, ranging from minutes to a couple of
hours (see Table 1). However, these half-lives are too short to be
compatible with the slow pharmacokinetics of nanomedicines, as
accumulation at the tumor-site via the EPR effect usually takes
several days [9,24,34e36]. This necessitates the use of radionu-
clides with longer half-lives e.g. indium-111 (2.8 days), zirconium-
89 (3.3 days) or iodine-124 (4.2 days).
Although both PET and SPECT radionuclides can be used to
image the pharmacokinetic properties of nanomedicines [37],
clinical PET cameras typically have greater sensitivity and higher
spatial and temporal resolution than clinical SPECT cameras
[38,39]. Therefore, PET imaging offers better image quality at lower
injected radioactivity doses. In contrast to SPECT, PET measure-
ments are quantitative, which makes PET the preferred imaging
method in clinical settings if a suitable labeling strategy exists.2.2. Conventional strategies for nanomedicines radiolabeling
Numerous methods for the labeling of nanomedicines have
been reported [52e56]. In general, they fall into two categories,
namely surface labeling and core labeling (Table 2).
1) Surface labeling
Classically, nanomedicines are radiolabeled by attaching a
radionuclide onto their surface [57,58]. This type of surface labeling
can be further divided into two broad categories, direct and indirect
labeling (Table 2A). In direct labeling, the radionuclide is incorpo-
rated or attached to the nanomedicine of interest without any
additional reaction steps. Not all nanomedicines can efﬁciently be
labeled using this direct approach. For example, some radiolabeling
reactions require harsh conditions (e.g. high temperatures and
strong bases), that the nanomedicine cannot withstand. In such
cases, the radionuclide can be introduced via an indirect labeling
strategy. In indirect labeling, the radionuclide is ﬁrst introduced
into a smaller synthon called a prosthetic group, which is thereafter
attached to the nanomedicine of interest. This approach is muchTable 1
Nuclear properties of radionuclides used in SPECT and PET imaging [40e42].
Radiouclide Modality Half-
lifea
Branching fract
(bþ)b (%)
Radionuclides suitable for imaging
slow clearing agents
123I SPECT 13.3 h e
111In SPECT 67.3 h e
64Cu PET 12.7 h 17.5
72As PET 25.9 h 88
89Zr PET 78.4 h 22.7
124I PET 100.2 h 22.8
Conventional PET/SPECT nuclides in
the clinic
99mTc SPECT 6.01 h e
11C PET 20.4min 99.8
68Ga PET 67.8min 89.1
18F PET 110min 96.7
Notes:
a Half-life is the time required for the activity to decrease to half of the original amou
b Fraction of radionuclide atoms that decay through positron emission.
c Range that the positron travels before it annihilates with an electron in the surroun
d Energies of emitted gamma photons that are used for SPECT imaging.
e Effective dose values represents the probability of cancer induction of low levels of io
out and represent typical values using the radionuclide in request (However, the value
radionuclide as well as the biodistribution of the tracer).
f n.d.¼ not determined.more versatile than direct labeling since the prosthetic group can
be chosen to ﬁt best the surface chemistry of the nanomedicine
[59e61]. Commonly used methods used for introducing prosthetic
groups include amide coupling, thiol-maleimide coupling, click
chemistry, glycosylation or oxime coupling. Very often, the surface
of nanomedicines has to be decorated with reactive groups that
enable indirect labeling [62,63].
2) Core labeling
Achieving stable attachment of radionuclides to the surface of
nanomedicines can be problematic. Enzymatic cleavage of covalent
bonds or sequestering of radiometals by endogenousmetal-binding
proteins may result in a release of radionuclides from the nano-
medicine [93]. As a consequence, the observed biodistribution of
radioactive signal would no longer represent the actual distribution
of the nanomedicine [94,95]. A solution to this problem is to
introduce the label into the core of the nanomedicine. In this
instance, release of radionuclide from the nanomedicine is pre-
vented unless the nanomedicine has degraded. Encapsulation (for
organic polymers, nanotubes or liposomes) or doping (for inorganic
nanoparticles) are commonly applied strategies (Table 2B).
In addition to these common strategies an elegant, but also
exotic method of core labeling for nanomedicines was reported by
Perez-Campa~na et al. [91,92]. In this method, [18/16O]Al2O3 nano-
particles were irradiated with a proton beam, which converted the
stable nuclides oxygen-18 and oxygen-16 within the nanoparticle
into the positron-emitting radionuclides ﬂuorine-18 and nitrogen-
13, respectively. So far, the work of Perez-Campan~a et al. remains
the only example of radiolabeling of nanoparticles by particle beam
activation. Although conceptually interesting, this approach is un-
likely to see widespread use in neither preclinical nor clinical set-
tings since the procedure is time-consuming, expensive and only
applicable to a certain type of nanoparticles.2.3. The radionuclide dilemma
As previously mentioned, the slow pharmacokinetics of nano-
medicines is only compatible with long-lived radionuclides, such as
iodine-124, zirconium-89, or indium-111. All of these radionuclidesion Maximum (average) positron
rangec in water (mm)
Gamma-photon
energyd (keV)
Effective dosee
[mSv/MBq]
e 159 0.017 [43]
e 171 and 245 0.346 [44]
2.9 (0.6) e 0.032 [45]
18.2 (5.2) e n.d.
f
4.2 (1.3) e 0.660 [46]
11.7 (3.4) e 0.580 [47]
e 140 0.010 [48]
4.5 (1.3) e 0.004 [49]
10.3 (3.6) e 0.017 [50]
2.6 (0.6) e 0.019 [51]
nt.
ding matter; living tissue mostly consists of water.
nising radiation. Presented values are taken from human dosimetry studies carried
can vary from tracer to tracer since the effective dose is depending on the used
Table 2
A general overview of commonly applied strategies for nanoparticle radiolabeling. (A) Surface labeling strategies. (B) Core labeling strategies.
Labeling method Examples of
suitable
radionuclides
References
A) Surface
labeling
Direct Covalent labeling 72As,124I,18F [64e68]
Chelator based labeling 64Cu,68Ga,11N [36,69e71]
Ionic/coordinate bond labeling 18F,89Zr,111In,
64Cu,68Ga
[72e77]
Indirect Prosthetic group labeling 11C,18F,64Cu,
99mTc,124I
[59,60,78
e84]
B) Core
labeling
Encapsulation Trapping of the radiolabel in the
internal cavity
111In,64Cu,99mTc [85e87]
Doping Incorporating the radionuclide into the
lattice
111In,64Cu,68Ga [88e90]
Stable nuclide
activation
Producing the imaging nuclide via an
external beam
13N,18F [91,92]
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nanomedicines over several days, which usually is the required
timeframe to achieve the necessary target-to-non-target ratios (see
Figs. 3 and 4A). However, use of such radionuclides results in a
substantial radiation dose for patients, which is commonly viewed
as unacceptable. Effective dose values for these radionuclides are in
the range of 0.3e0.7 mSv/MBq (see Table 1) and can easily result in
patient doses of 40e50mSv per scan [44,46,47]. The annual dose
constraint recommended by the International Commission on
Radiological Protection is 20mSv for patients undergoing diag-
nostic or therapeutic procedures with radiopharmaceuticals [96].
Therefore, received doses using nanomedicines labeled with long-
lived radionuclides restrict repeated applications and the absolute
amount of radioactivity that can be administered. In addition, long-
lived positron emitters (89Zr, 124I) also tend to have low bþ-
branching fractions, which can decrease quantitative accuracy and
the quality of the obtained images. In comparison, conventional
short-lived PET radionuclides like carbon-11, ﬂuorine-18 and
gallium-68 decay almost exclusively through positron emission and3 The radionuclide dilemma: Long-lived radionuclides have to be used to be able
to image the slow pharmacokinetics of nanomedicines. These long-lived radionu-
clides result in high radiation doses. Short-lived radionuclides are not compatible
with the slow pharmacokinetics of nanomedicines. As such, no perfectly suited
radionuclides exist for this application.their effective dose values are more than an order of magnitude
lower, 0.005e0.02 mSv/MBq. However, radiolabeling of nano-
medicines with these short-lived radionuclides will not provide
high enough signal at the required imaging time. This represents
the radionuclide dilemma.3 Finally, radionuclides such as copper-
64 and iodine-123, with moderate half-life (12.7 h and 13.3 h,
respectively) and a relatively low radiation burden (approx. 0.03
mSv/Bq) are also not capable of imaging nanomedicines beyond
2e3 days post-administration. This timeframe is typically insufﬁ-
cient to obtain optimal target-to-non-target contrast and conse-
quently, the best imaging quality.
An elegant strategy to circumvent this dilemma is pretargeting.
It allows the use of short-lived PET radionuclides with low effective
dose values and beneﬁcial radiophysical imaging properties.
Therefore, the use of long-lived radionuclides can be circumvented,
and better imaging contrast can be obtained at earlier timeframes
[97].
In the following sections, the concept of pretargeting will be
explained, as well as interactions and chemical reactions used for
such a strategy. In addition, a demonstration of how the application
of pretargeted imaging and therapy could facilitate the translation
of nanomedicines from preclinical research into clinical practice
will be given.
Fig. 3. Nanomedicines that passively accumulate into the tumor via the EPR effect need long timeframes to achieve good target-to-non-target contrast. (A) Time-dependency of the
passive accumulation of 64Cu-labeled glycol chitosan nanoparticles (64Cu-CNPs) in SCC7 tumor bearing mice. At early time-points the contrast between tumor and background is
low. However, the contrast increases over time as 64Cu-CNPs are excreted. Figure modiﬁed from Ref. [9]. (B) Biodistribution proﬁle of 64Cu-MM-302 (64Cu-labeled HER2-targeted
PEGylated liposome containing doxorubicin) in patients with metastatic breast cancer. The accumulation proﬁle of 64Cu-MM-302 is independent of the targeting ligand, hence
dictated primarily by the EPR effect. Immediately after administration, 64Cu-MM-302 activity is primarily conﬁned to the blood pool. Only after 24 h and 38 h, uptake of 64Cu-MM-
302 is evident in liver, as well as in various tumor lesions. Figure modiﬁed from Ref. [9].
Fig. 4. Different approaches for nuclear imaging of nanomedicines. (A) Conventional imaging (B) Pretargeted imaging (C) Pretargeted imaging with clearing agent.
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Fig. 5. SPECT/CT images from (A) Conventional imaging of 125I-labeled anti-endolgin (CD105) mAbs targeting B16 tumors (B) Pretargeted imaging of a TAG-72 targeting mAb (CC49)
with [111In]In-DOTA-PEG11-Tz 1 as a secondary agent in colon carcinoma xenografts (C) Pretargeted imaging with clearing agent for the mAb CC49/[111In]In-DOTA-PEG12-Tz 1
pretargeting system (more than a 100-fold higher imaging contrast compared to B). Abbreviations of organs: B¼ bladder; Li¼ liver; Lu ¼ Lungs; Sp¼ spleen; T¼ tumor. Images
from Refs. [97,100,101].
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3.1. The concept
A pretargeted imaging approach circumvents the drawbacks
usually related with conventional imaging (see 2.3: The radionu-
clide dilemma) (Fig. 4A). This is possible since in pretargeted im-
aging, the slow passive targeting process of nanomedicines is
separated from the actual imaging by using a so called pretargeting
pair, which consists of a tagged nanomedicine (primary targeting
agent) and a secondary imaging agent (Fig. 4B).
The approach is divided into two steps. In the ﬁrst step, the
nanomedicine is injected and allowed to accumulate in the target
tissue over a sufﬁcient period of time, usually days. In the second
step, the imaging step, a radiolabeled secondary imaging agent is
administered [98,99]. The secondary imaging agent will either
interact or covalently bind to the compatible tag on the nano-
medicine (depending onwhich type of pretargeting pair is used). As
a result, the target accumulation of the nanomedicine can be
imaged in an indirect fashion. Preferably, the secondary imaging
agent should be designed so that it is rapidly cleared and radio-
labeled with a short-lived, high positron-emitting radionuclide, e.g.
carbon-11, ﬂuorine-18 and gallium-68. Consequently, the absorbed
radiation burden will be lower, and the imaging contrast higher. In
order to reduce the period of time between the accumulation and
the imaging step, a clearing agent step can be added (Fig. 4C). The
clearing agent removes circulating nanomedicines from the blood
stream and usually transports them to the liver or spleen within a
few hours [97]. Fig. 5 compares the image quality that can be ob-
tained using conventional (Fig. 5A), pretargeting (Fig. 5B) and
pretargeting with clearing agent (Fig. 5C) strategies to image slow
clearing monoclonal antibodies (mAbs). Monoclonal antibodies as
nanomedicines have slow pharmacokinetic properties.4 Aggregation adducts of mAbs are more prone to be recognized by the reticulo-
endothelial system due to their increased size. In addition, they can grow to such a
size that they are stuck in small blood capillaries (e.g. in the lungs). Finally, ag-
gregation of mAbs could inﬂuence the mAbs binding site, which can result in a loss
of target afﬁnity.
5 For instance, modifying the surface of the nanomedicine in order to make it
hydrophilic and/or charged prevents inter-particle aggregation.3.2. The potential of pretargeted imaging for nanomedicines
Drug delivery strategies based on passively targeted nano-
medicines have the potential to improve current cancer therapy.
Then again, the magnitude of the EPR effect varies between pa-
tients, and as such not all patients respond to nanomedicinetreatment approaches. Therefore, it is important to distinguish
potential responders from likely non-responders (personalized
medicine). In fact, the use of passively targeted nanomedicines on
non-responders would not only be ineffective, but harmful. As
discussed (see 3.1), pretargeting strategies hold great potential for
imaging of long-circulating nanomedicines because they have the
possibility to reduce the radiation burden for patients and increase
imaging contrast. In the context of companion diagnostic imaging
for mAb-based medicines, pretargeted imaging has already
attracted a lot of interest [102,103].
However, only a few preclinical studies involving pretargeted
imaging with passively targeting nanomedicines have been re-
ported [104e107]. This is surprising considering the potential
clinical impact of nanomedicines. In fact, nanomedicines are better
suited for pretargeted imaging than mAbs because nanomedicines
can carry more reactive tags. This is important since higher tag-
loading increases the likelihood for pretargeting strategies to
occur [103]. Typically, only 5e10 reactive tag groups can be intro-
duced into mAbs without impairment of their targeting properties
[97,108e110]. Higher numbers lead to aggregation [111e114] and
aggregation, in turn, prevents the mAb from accumulating at the
target-site.4 High reactive tag-loading of mAbs can also lead to
interference with the target antigen recognition and prevent se-
lective binding of the mAb. In contrast, nanomedicines can be
designed in such a way that aggregation is prevented5 and conse-
quently, higher loadings of reactive tags per nanomedicine can be
realized (Fig. 6). The maximum number of reactive tags for a
passively targeted nanomedicine has not been thoroughly investi-
gated, but at least an 8-fold higher tag load compared to mAbs was
reported to be achievable without aggregation [115].
Fig. 6. Tag-load and aggregation probability. (A) In highly modiﬁed mAbs only a fraction of tags retains reactive. (B) Nanomedicines permit high tag-loadings without triggering
aggregation.
6 If the clearance of the secondary imaging agent is too rapid there is a lower
probability for the pretargeted interaction to occur, resulting in lower target
accumulation.
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In general, there are two types of pretargeting systems: (I) non-
covalent high-afﬁnity interactions and (II) covalent bond forma-
tions via bioorthogonal chemistry. The ﬁrst pretargeting strategies
developed fall within the ﬁrst category. They rely on high-afﬁnity
interactions between biomolecules [102] such as the bispeciﬁc
antibody (bAb) and hapten recognition, the interaction between
(strept)avidin and biotin, and the hybridization of complementary
oligonucleotides. Modern pretargeting strategies rely on bio-
orthogonal chemical reactions between small molecule tags. Bio-
orthogonal reactions are deﬁned as: “chemical reactions that neither
interact nor interfere with a biological system.” e C.R. Bertozzi (2003)
[116].
3.3.1. Non-covalent high-afﬁnity interactions
Pretargeting strategies based on non-covalent high-afﬁnity in-
teractions involve biological molecules that tightly interact with
each other. These interactions are governed by high afﬁnity and
highly speciﬁc hydrogen bonding interactions that occur in a bio-
logical medium.
3.3.1.1. Bispeciﬁc antibody and hapten recognition. One of the most
extensively studied pretargeting strategies involves the use of bis-
peciﬁc antibodies (bsAbs) and radiolabeled haptens. A bsAb is an
artiﬁcially produced antibody (Ab) that has been engineered to
target two different antigens or epitopes (the area of antigen
recognized by the immune system) [117], whereas a hapten is a
non-immunogenic small molecule e.g. a peptide that binds spe-
ciﬁcally to an Ab with high afﬁnity (Kd¼ 105e1010M) [118,119].
Reported rate constants for the interaction have been within the
range of 1035M1 s1 [120].
For pretargeted imaging, the hapten is radiolabeled and
administered after the bsAb has localized at the target-site (using
the tumor binding side of a bsAb). Afterwards, the radiolabeled
hapten binds to the speciﬁc hapten binding-site of the bsAb. To
ensure high target-to-background ratios, haptens have to be
designed in such a manner that they possess an adequate circula-
tion time before they are excreted. The combination of high
selectivity, fast targeting and reasonable clearance allow haptens to
be used for in vivo pretargeting strategies.
3.3.1.1.1. In vivo imaging applications. The ﬁrst application of
pretargeted tumor imaging was described in 1986 and made use of
the bsAb and hapten recognition [121]. In this initial report, micebearing syngeneic KHJJ adenocarcinoma tumors were administered
with the bsAb, WC3A11 IV. After 20 h, a cobalt ethyl-
enediaminetetraacetic acid (EDTA) hapten chelate bound to human
transferrin was administered as a clearing agent and the resulting
aggregate was cleared through the liver [119]. In the ﬁnal step
(Fig. 7A), an 111In-labeled EDTA-based hapten ([111In]In-BLEDTA IV
2) (Fig. 7B) was administered 1 h after the clearing agent. A tumor
uptake of 1.4% injected dose per gram (ID/g) was observed 3 h post
injection (p.i.) compared to 0.72% ID/g without bsAb pretreatment.
Tumor accumulation without a clearing agent was much higher
(4.07% ID/g), however the tumor-to-blood ratio was lower (0.68
without clearing agent compared to 8.72 with clearing agent). As a
consequence, tumor visualizationwas best when the clearing agent
was used. Despite the groundbreaking success of this initial study,
the overall tumor uptake was quite low and imaging contrast was
poor (Fig. 7C).
As an alternative, Stickney et al. developed a novel 111In-labeled
EDTA-based hapten, [111In]In-EOTUBE 3 (Fig. 8A). This probe was
evaluated in mice bearing human colon cancer xenografts and
compared with the previously developed probe, [111In]In-BLEDTA
IV 2 (Fig. 7B). In this study, [111In]In-BLEDTA IV 2 and [111In]In-
EOTUBE 3were administered 24 h after intravenous administration
(i.v.) of the bsAb (14 mg) [118]. The radioactivity was co-
administered with a dose of 3 mg of the bsAb as a carrier. The car-
rier protein was included to prolong the plasma retention of the
otherwise rapidly clearing 111In-labeled hapten.6 This strategy is
effective because the hapten and the bsAb bind reversibly. There-
fore, over time the hapten is released from the circulating bsAb and
made available to bind to the pretargeted bsAb in the tumor. As a
consequence, the blood elimination half-life for the hapten is
increased. Using this procedure, the original probe, [111In]In-
BLEDTA IV 2, showed an increased tumor uptake of 7% ID/g 24 h p.i.
(determined by ex vivo biodistribution) and the novel probe, [111In]
In-EOTUBE 3, resulted in an even higher uptake (18.5% ID/g) using
the same procedure. These results inspired Stickney et al. to
advance [111In]In-EOTUBE 3 to clinical studies, in which 14 patients
between 62 and 82 years of age with metastatic or recurring
adenocarcinoma of the colon were included. They were co-
administered with [111In]In-EOTUBE 3 (Fig. 8A), and a small
Fig. 7. (A) Representation of the pretargeting system using bsAbs and a radiolabeled hapten. In the ﬁrst step, the bsAb was injected intravenously and allowed to reach maximal
tumor accumulation. In the second step a clearing agent (human transferrin functionalized with the Co-chelated hapten) was administered to clear any remaining bsAb from the
blood pool. In the third step the 111In-labeled hapten was administered and allowed to accumulate at the target-site. The 111In-labeled hapten rapidly cleared from the blood stream
and imaging can proceed. (B) Structure of [111In]In-BLEDTA IV 2, BLM¼ bleomycin. (C) Posterior gamma camera pinhole images of KHJJ tumor bearing mice. Left Image: control
mouse with [111In]In-BLEDTA IV 2 21 h p.i. Middle image: mouse pretreated with WC3AI IV followed 21 h later by injection with [111In]In-BLEDTA IV 2 Right image: mouse pre-
treated with WC3AI IV followed by injection of clearing agent 20 h later and then 1 h later injection of [111In]In-BLEDTA IV 2 21 h p.i. Arrows indicate T¼ Tumor; L¼ Liver; K ¼
Kidney; B ¼ Bladder. Fig. 7C modiﬁed from Ref. [119].
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known lesions, 20 were detected [118].
3.3.1.1.2. Afﬁnity enhancement strategy and state-of-the-art
studies. The use of a bsAb as a carrier protein was successful in
enhancing tumor uptake of the fast clearing radiolabeled hapten,
however, it also resulted in longer circulations times. This is a
problem for imaging purposes. Adequate uptake values were only
observed after 24 h. In an attempt to solve this problem an alter-
native strategy was proposed using bivalent haptens. Bivalent
haptens are capable of binding to two neighboring bsAbs at once.
This increases the afﬁnity between the hapten and the bsAb.
Consequently, an increased retention at the target is expected and
furthermore, this approach could eliminate the need for a clearing
agent. In this respect, an 111In-labeled bivalent hapten was devel-
oped and used to target an anti-CEA anti-diethylene-
triaminepentaacetic acid (DTPA)-In-bsAb in a pretargetingexperiment using LS174T tumor bearing mice. Tumor-to-blood ra-
tios were higher (7.9± 1.1) when compared to values obtained us-
ing monovalent haptens (4.5± 1.0) or directly labeled Abs
(2.0± 0.3) [122]. The use of bivalent haptens made the bsAbs and
hapten recognition strategy attractive for applying short lived ra-
dionuclides such as gallium-68 or ﬂuorine-18 and several studies
have been successfully published applying this strategy (Fig. 9)
[123,124].
3.3.1.1.3. Application to nanomedicines. Due to the nature of the
interaction, the bsAb and hapten recognition is limited to Ab-based
nanomedicines. For example, Rauscher et al. reported a study in
which the tumor accumulation of liposomes was increased using a
pretargeting strategy. First, a liposome modiﬁed with a bsAb was
administered and allowed to speciﬁcally bind. Afterwards, a radi-
olabeled liposome functionalized with multiple haptens was
administered as the secondary imaging agent. A tumor uptake of
Fig. 8. Structure of [111In]In-EOTUBE 3.
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uptake was higher compared to the uptake applying conventionally
radiolabeled liposomes (4.5± 0.45% ID/g) [125].
3.3.1.1.4. Concluding remarks e bispeciﬁc antibodies and hapten
recognition. The bsAb and hapten recognition has been extensively
studied in patients and clinical trials are ongoing [126e128]. SomeA) B)
D)
Fig. 9. PET maximum-intensity-projection images recorded in 1 patient of each cohort. A
nodes in patient 1. (B) Cervical node; lumbar and femoral bones foci in patient 2. (C) Supra
nodes, lung, liver, and bone foci in patient 4. (E) Supradiaphragmatic nodes and liver foci ichallenges that could hinder the widespread use of this system,
especially for companion diagnostic imaging, include the immu-
nogenic response towards the bsAb and challenges in producing
them.3.3.1.2. (Strept)Avidin-biotin interaction. Another extensively stud-
ied pretargeting approach is based on the (strept)avidin-biotin
interaction. Avidin is a tetrameric 66-kDa glycoprotein commonly
found in egg whites. Streptavidin is a non-glycosylated 60-kDa
variant, which is found in Streptomyces avidinii culture [108].
Avidin and streptavidin are both comprised of four identical sub-
units that each bind to a single biotin unit. Biotin is a 244-Da water
soluble small molecule that is also referred to as vitamin B7
(formerly vitamin H or coenzyme R) [102]. The afﬁnity between
(strept)avidin and biotin is one of the strongest known non-
covalent interactions (Kd¼ 1015M) (Fig. 10) with rate constants
in the order of 107M1 s1 [129e132]. The interaction has been
applied in numerous aspects of biotechnology e.g. in immunolog-
ical assays, electron microscopy, afﬁnity chromatography, and
nucleic acid hybridization [133].
3.3.1.2.1. Pretargeting strategies. I) Streptavidin vs. avidin:
Although streptavidin and avidin have essentially identical binding
afﬁnity for biotin, their use is highly dependent on the intended
application as they each have different in vivo pharmacokinetics.
For example, avidin is often used as a clearing agent since it rapidlyC)
E)
rrows showed foci considered as pathologic by immuno-PET. (A) Supradiaphragmatic
diaphragmatic nodes and liver and heart lesions in patient 3. (D) Supradiaphragmatic
n patient 5. Figure modiﬁed from Ref. [124].
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Fig. 11. Demonstration of antibody dimer formation following addition of streptavidin
to biotinylated antibodies.
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often used in mAb conjugates or as a radiolabeled secondary im-
aging agent because streptavidin displays higher in vivo stability
and longer circulation times than avidin [135,136].
II) (Strept)avidin vs. biotin: The (strept)avidin-biotin interac-
tion can in principle be applied in twoways for pretargeted imaging
[108,135,137,138]. Either the primary targeting agent can be func-
tionalized with (strept)avidin and biotin being used as the sec-
ondary imaging agent or the primary targeting agent can be
functionalized with biotin and (strept)avidin being used as the
secondary imaging agent. Usually, the ﬁrst option is applied in
pretargeted imaging because (strept)avidin circulates much longer
than biotin. Shorter circulation time for the secondary imaging
agent lead to higher imaging contrast. Of course, only if the sec-
ondary imaging agent is able to bind effectively to the tagged pri-
mary targeting agent in the respective timeframe. Therefore, biotin
is better suited to be used as the secondary imaging agent [137].
Biotin can be radiolabeled by applying a wide variety of strategies,
including chelators such EDTA, DTPA and 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). These
chelators can be used to incorporate a broad set of radiometals
[108].
A concern in using radiolabeled biotin as a secondary imaging
agent is that endogenous biotin can block the binding sites of
(strept)avidin and thus prevent radiolabeled biotin to bind to the
preadministered nanomedicine. This effect is observed and dis-
cussed in some studies, but not reported to be problematic in other
studies [137,139,140].
3.3.1.2.2. Functionalization strategies. Standard conjugation
methods can be used to functionalize nanomedicines with (strept)
avidin. However, a more exotic, but frequently applied, strategy also
exists. In this approach, biotin is ﬁrst coupled to the primary tar-
geting agent and then this conjugated biotin is functionalized with
(strept)avidin (Fig. 11). (Strept)avidin has four biotin binding sites,
therefore this approach leaves three biotin binding sites available.
However, dimers and polymeric structures are usually formed us-
ing this approach, which have to be separated from the desired
product [108].
Conjugation of biotin to the primary targeting agent can be
achieved using biotinylating agents such as sulfosuccinimidyl 6-
(biotinamido) hexanoate for amine groups, p-diazobenzoyl-biocytin for tyrosyl and histidyl moieties or 3-(N-mal-
eimidopropionyl)biocytin for thiol groups [133].
3.3.1.2.3. In vivo imaging: proof-of-concept. The ﬁrst successful
in vivo pretargeting experiments using radiolabeled biotin was
performed with implanted avidin coated beads in 1987 by Hnato-
wich et al. [135]. Only two mice were used in this initial study. The
ﬁrst mouse was injected intraperetoneal (i.p.) with ~120 000 par-
ticles (45e165 mm) that were coated with avidin, while the second
mouse received underivatized beads. Immediately after the
administration of the particles, each mouse was given an 111In-
labeled biotin derivative. Imaging was performed 2 h p.i. High
radioactive uptake corresponding to the location of the implanted
avidin-coated beads was observed (Fig. 12A, right), whereas only
kidney and bladder accumulation was detected in the control ex-
periments (Fig. 12A, left).
This and follow-up studies encouraged Hnatowich and col-
leagues to translate the biotin-(strept)avidin based pretargeting
approach to clinical application in 1990 [137]. Ten patients aged of
43e77 with squamous cell carcinoma were administered a
streptavidin-functionalized HMFG1 mAb targeting this tumor type.
After 2e3 days, an 111In-labeled DTPA-functionalized biotin deriv-
ative was administered, and images were obtained 2 h p.i. As a
negative control, the same patients were injectedwith the [111In]In-
DTPA-biotin in the absence of the streptavidin-conjugated mAb.
The negative control study was carried out 2e3 weeks before the
pretargeted imaging experiment. Only 3 patients displayed an
observable improvement in image quality when pretreated with
streptavidin-functionalized mAbs compared to the control experi-
ments (Fig. 12B). No toxic effects were observed in this study.
However, all patients did develop anti-streptavidin mAbs and thus
showing an immunogenic response [142].
3.3.1.2.4. Clearing agents. The use of clearing agents to improve
image contrast for mAb based strategies was ﬁrst demonstrated
using the (strept)avidin-biotin interaction on a conventionally 125I-
labeled IgG antibody. Up to 20% of the initial activity was still
circulating 24 h p.i. In order to reduce this amount, the mAb was
functionalized with biotin and the fast clearing avidin was used to
clear the biotynalyated mAb construct from circulation. After a
single injection of avidin, the amount of radioactivity in the blood
was reduced by 90e95% within 15min. The majority (70%) of the
radioactivity was cleared through the liver [134]. Although this
strategy increases the imaging contrast and reduces the radiation
dose that is received due to the slow clearance of the mAb, the
strategy does not minimize the radiation dose that is received due
to the slow target accumulation of the mAb.
This was addressed by Paganelli et al. in 1990 by applying a
pretargeting strategy combined with a clearing agent step. How-
ever, Paganelli et al. used a slightly different variant of the clearing
agent approach described in Fig. 4C [143e145]. In short, a bio-
tinylatedmAbwas ﬁrst administered and allowed to reachmaximal
target accumulation. Afterwards, avidin was administered. This
Ki
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Fig. 12. (A) Whole body images of two mice injected i.p. with avidin-functionalized (right) and unfunctionalized (left) beads followed 2 h later with 111In-labeled biotin. Signal in the
upright corner of the left image represents the location of the avidin-coated beads. (B) Images of the anterior chest and upper abdomen of the same lung cancer patient
administered with 111In-labeled biotin after receiving a streptavidin-functionalized antibody 2 weeks (left) or 2 days (right) prior. (C) mPET/CT images of [68Ga]Ga-ATRIDAT-BIO (30
MBq) injected in avidin treated nude mice xenografted with A549 tumor cells. Abbreviations of organs: T¼ Tumor; Beats¼ avidin-coated beads; L¼ Liver; Ki¼ Kidney; Bl¼ Bladder.
Figure modiﬁed from Refs. [135,137,141].
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mAbs circulating in the blood stream and clear it via liver excretion
and (II) avidin should bind to the biotinylatedmAb at the target and
increase the numer of binding sites (this is possible since only one
of the four domains of avidin binds to the biotinylated mAb at the
target). Finally, radiolabeled biotin was administered to target the
avidin-functionalized biotinylated mAb (Fig. 13). Compared to the
standard 2-step pretargeting procedure (Fig. 4B), this 3-step pro-
cedure can increase imaging contrast between the blood and target
tissues up to 10-fold [146].
However, the aforementioned 3-step approach raises the
question as to why it would be preferable to functionalize the mAb
in vivo as opposed to prior to injection. First, the formation of mAb
aggregates (see Fig. 11)) is eliminated and thus tedious puriﬁcation
of the end product is avoided. Furthermore, the injected avidin can
bind to endogenous biotin and clearing it from the system before
the radiolabeled biotin is administered. This avoids any potential
blocking of the streptavidin binding units at the target-site by
endogenous biotin.
3.3.1.2.5. Application to nanomedicines. The (strept)avidin-
biotin interaction has been applied to pretargeted imaging of a
bifunctional multivalent phage in a murine prostate cancer model.
Both the standard pretargeting strategy (without applying clearing
agents) (Fig. 4B) and the modiﬁed strategy developed by Paganelli
et al. (Fig. 13) were used in this study [147]. In the standard
approach, a biotinylated phage was injected into SCID mice bearing
PC-3 human prostate carcinoma tumors. After 4 h, an 111In-labeled
DTPA streptavidin conjugate was injected and imaging was per-
formed after an additional 4 h. In themodiﬁed approach, micewere
administered with avidin 4 h after the biotin-functionalized phage
were injected and 24 h before 111In-labeled biotin. The modiﬁed
procedure resulted in a higher tumor uptake (4.34% ID/g) than the
standard approach (0.67% ID/g).
3.3.1.2.6. Concluding remarks e (Strept)Avidin-biotin interaction.
Although there are recent preclinical developments applying this
strategy (Fig. 12C) [141,148], its use in clinical applications has seen
a decline. This is evident by the lack of registered on-going clinical
trials using this system for pretargeting (i.e. ClinicalTrails.gov). In a
head-to-head comparison of this system and the bsAb-hapten
pretargeting system, it was found that the latter was superior
[132]. The reason for this was a better biodistribution proﬁle, better
therapeutic efﬁcacy of a90Y-labeled hapten secondary agent, and
reduced immunogenicity. Despite early promising clinical results,this strategy suffers from a number of drawbacks. This includes
development of an immunogenic response, difﬁculties in producing
streptavidin conjugates, and inﬂuence on target uptake of the pri-
mary targeting agent due to the large size of streptavidin.3.3.1.3. Hybridization of complementary oligonucleotides. The high
afﬁnity of the non-covalent interaction arriving fromWatson-Crick
base pairing can also be utilized for pretargeting strategies. In this
instance, high numbers of base pairs are used to let oligonucleo-
tides hybridize via hydrogen-bonding that occurs between two
chains of complementary nucleotides. In DNA, adenine forms a
base pair with thymine and guanine forms a base pair with cytosine
(Fig. 14A). The same interaction is present in RNA except thymine is
replaced by uracil [149,150]. The resulting hybridization gives sec-
ond order rates in the range of 104M1 s1 for complementary
oligonucleotides. Reaction kinetics that make the system attractive
for pretargeted imaging [151]. However, DNA- or RNA-based olig-
omers are both rapidly degraded in vivo by nucleases, which pre-
vents it use for in vivo imaging strategies [152e154].
Phosphorodiamidate morpholino oligomers (PMOs), peptide
nucleic acid (PNA) and phosphorothioates derivatives have been
designed to overcome this problem (Fig. 14B and C) [155e157]. In
the following, our discussion will focus on PMOs and PNAs since
this strategy is by far more applied.
3.3.1.3.1. Phosphorodiamidate morpholino oligomers (PMOs).
PMOs are oligonucleotide analogs comprised of DNA base pairs
attached to an achiral, non-ionic backbone made up of morpholine
groups linked through phosphorodiamidate groups (Fig. 14B). This
backbone replaces the ribose/furanose phosphodiester-linked
moieties present in DNA and RNA. An advantage of this modiﬁca-
tion is that water-soluble PMOs are resistant to both nucleases and
proteases, while still able to bind to complimentary base pairs
through Watson-Crick hydrogen bonding [156]. The ﬁrst in vivo
application of this strategy was carried out in nude mice bearing
LS174T tumors [158]. For pretargeting, 50 mg of the PMO-modiﬁed
anti-CEA antibody (MN14) was administered and after 48 h
a99mTc-labeled complimentary PMO (cMORF) was injected. Images
and ex vivo biodistribution studies were performed 3 h and 24 h p.i.
High tumor accumulation of 1.8% ID/g (3 h p.i.) and 1.7% ID/g (24 h
p.i.) was observed in mice injected with anti-CEA mAb. Control
animals showed only an uptake of 0.09% ID/g 3 h p.i. and 0.05% ID/g
24 h p.i.. Tumor visualization using a scintillation camera was
challenging at 3 h p.i. due to high background radioactivity in the
Fig. 13. Representation of the pretargeting system using biotin and avidin. In the ﬁrst step the biotinylated mAb is injected i.v. and allowed to reach maximal tumor accumulation. In
the second step avidin is injected as a clearing agent to clear any remaining biotinylated mAb through the liver and as a mean to functionalize the biotinylated mAb at the tumor-
site. In the third step 111In-labeled biotin is administered and accumulates at the tumor-target site. Finally, 111In-labeled biotin rapidly clears through the kidneys and imaging can
proceed.
Fig. 14. (A) Waston-Crick base pairing in DNA between guanine and cystosine and adenine and thymine, respectively. (B) General structure of phosphorodiamidate morpholino
oligomers (PMOs). (C) General structure of peptide nucleic acids (PNAs).
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aging contrast could be observed at 3 h p.i. (Fig. 15B). This imaging
contrast was comparable with the one observed 24 h p.i. (Fig. 15C).
Since this report, a number of studies using PMOs have been
reported with radionuclides for SPECT imaging [159e165] or
radiotherapy [166,167]. However, there are no reports of PET im-
aging agents or clinical studies in the present literature.
3.3.1.3.2. Peptide nucleic acids (PNAs). Peptide nucleic acids(PNAs), like PMOs, are oligonucleotide derivatives that have a
modiﬁed backbone. In this case the sugar phosphatemoieties of the
DNA/RNA backbones have been replaced with a peptide backbone,
typically made up of N-(2-amino-ethyl)-glycine units (Fig. 14C).
Similar to the PMOs, the PNAs are achiral, non-ionic structures that
are enzymatically stable, but still able to undergo Watson-Crick
hydrogen bonding [157]. A pretargeting PNA-based approach was
ﬁrst reported in 1997 [168]. In this study mice bearing LS174T
Fig. 15. Whole body gamma camera images of mice bearing LS174T tumors. Animals
on the right were administered with the PMO-functionalized anti-CEA mAb and then
48 h later with the 99mTc-labeled cMORF. Animals on the right were only administered
the 99mTc-labeled cMORF. (A) Images obtained 3 h p.i. (B) Images obtained 3 h p.i. after
removing the urine. (C) Images obtained 24 h p.i. Figure modiﬁed from Ref. [158].
Fig. 17. PET images of FaDu tumor bearing mice administered with NOTA'3-C225-(c-L-
DNA)1.5 24 h prior to administration of [64Cu]Cu-NOTA0-L-DNA-10 kDa- PEG. Repre-
sentative PET images (maximum intensity projection) at different time points after i.v.
injection. Images were obtained 1min, 5min, 20min, 50min, 24 h, 48 h, and 72 h p.i.
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PNA (150 mg) (streptavidin accumulates in tumors) [108]. After a 5 h
lag time, a 99mTc-labeled complimentary PNA (cPNA) derivativewas
administered. SPECT imaging 4 h p.i. showed higher tumor uptake
in the PNA pretreated group (0.29% ID/g) compared to those that
did not receive PNA-functionalized streptavidin (0.10% ID/g). The
same trend was observed for the tumor-to-muscle (thigh) ratio (3.5
vs 1.7). Overall the observed tumor uptake was low in this initial
study, yet encouraging for further optimization [165,169,170].
Leonidova et al. were the ﬁrst ones to demonstrate successful tu-
mor targeting with this approach using an Ab conjugate [169]. In
this study, mice bearing A431 tumor xenografts were administered
a PNA-functionalized Ab (cetuximab), which targets the extracel-
lular domain of the epidermal growth factor receptor (EGFR).
A 99mTc-labeled complimentary PNA was 24 h afterwards injected.
Tumor visualization was possible using SPECT/CT 1 h p.i. (Fig. 16A).
In contrast, the control experiment, in which no Ab conjugate was
injected, did not result in any tumor visualization (Fig. 16B). The
tumor-to-muscle ratio achieved in the pretargeting study was 8.29.
However, a low tumor-to-blood ratio was observed (0.48) due to
incomplete elimination of the Ab from the blood. Despite prom-
ising preclinical studies, there are no current reports of this system
being tested or used in a clinical setting.
3.3.1.3.3. Non-natural L-oligonucleotides. Recently, non-natural
L-oligonucleotides (L-ONs), resistant to enzymatic degradation
have been developed for pretargeted imaging. Schubert et al. re-
ported the ﬁrst study using L-ONs [171]. In this study, the EGFR
speciﬁc mAb cetuximab (C225) and a64Cu-labeled 1,4,7-
triazacyclononane-1,4,7-triacetic acid (NOTA) derivative wereFig. 16. SPECT/CT maximum intensity projections of mice bearing A431 tumor xenografts
tration of [99mTc](Tc-Dpa)-(Cys-PEG10 kDa)-PNA. (B) Mouse was administered [99mTc](
Figure modiﬁed from Ref. [169].both functionalized with L-ONs. The functionalized mAb (NOTA'3-
C225-(c-L-DNA)1.5, 4 nmol) was administered to FaDu tumor
bearing mice and 4 h later the 64Cu-labeled complementary L-ON
([64Cu]Cu-NOTA0-L-DNA-10 kDa-PEG) was injected. Tumor visuali-
zation with PET was possible 50min p.i. (Standard Uptake Value
(SUVmean)¼ 0.7± 0.03), however, the highest tumor uptake was
observed at 24 h p.i. (SUVmean¼ 0.9± 0.2) (Fig. 17). A tumor-to-
muscle-ratio of 10.59± 5.02 was determined following ex vivo
biodistribution. These values were lower than what was found for
the directly labeled mAb, where the SUVmean for the tumor was
1.5± 0.1 at 23 h p.i. and the tumor-to-blood ratio was 14.6± 1.8.
Lower accumulation in the pretargeted case could be attributed to
high liver accumulation of [64Cu]Cu-NOTA0-L-DNA-10 kDa-PEG and
internalization of the C225 mAb. Both incidents lower the possi-
bility of pretargeting (less secondary imaging agent available and
less accessible mAb since the primary imaging agent cannot cross
cell membranes) [171].
In general, this pioneering work demonstrates the utility of this
approach for in vivo imaging. However, optimization is required in
order to incorporate short-lived radionuclides for clinical
translation.
3.3.1.3.4. Concluding remarks e hybridization of complementary
oligonucleotides. Despite promising preclinical experiments with
mAbs and proteins/peptides, pretargeted imaging using1 h p.i. (A) Mouse was administered (NOTA)3- C225-Cys-c-PNA 24 h prior to adminis-
Tc-Dpa)-(Cys-PEG10 kDa)-PNA without pretargeting with (NOTA)3-C225-Cys-c-PNA.
Figure modiﬁed from Ref. [171].
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applied to other systems, such as nanoparticles or polymers. No
clinical studies have been reported so far.3.3.2. Covalent bond formations via bioorthogonal chemistry
For a reaction to be classiﬁed as bioorthogonal, several re-
quirements have to be fulﬁlled. First, the participating groups need
to be inert towards other biological functionalities such as amino
acid residues, nucleic acids, etc. Second, the groups have to be able
to react with each other under biocompatible conditions. Finally,
the reaction must be fast and speciﬁc. A number of bioorthogonal
reactions have been described since the introduction of the term
[172e177]. The ﬁrst being the Staudinger ligation, inwhich an azide
and a phosphine react to form an amide bond [172]. Later, a second
version of the ligation was developed, the traceless Staudinger
ligation. In comparison to the original Staudinger ligation, this re-
action proceeds via an additional rearrangement that cleaves off
the highly lipophilic phosphine adduct [173,174]. Both Staudinger
ligations are limited by rather slow rate constants (for in vivo
chemistry) and the tendency of phosphines to oxidize in vivo [178].
Nowadays, other bioorthogonal reactions have been shown to serve
as better alternatives for in vivo applications, two of them, the
strain-promoted azide-alkyne [3 þ 2] cycloaddition (SPAAC) and
the tetrazine ligation will be discussed in the following sections.3.3.2.1. Strain-promoted azide-alkyne [3 þ 2] cycloaddition (SPAAC).
In 2001 Kolb, Finn and Sharpless coined the term click chemistry.
The aim of click chemistry was to easily connect fragments via a
heteroatom linkage. The reactions should be fast and selective. In
addition, few or no by-products should be formed, and the reaction
should be carried out in water or benign solvents [179]. The reac-
tion that launched the ﬁeld of click chemistry was the Cu-catalyzed
Huisgen [3 þ 2] cycloaddition between azides and alkynes, also
called the Cu-catalyzed azide-alkyne [3 þ 2] cycloaddition (CuAAC)
(Fig. 18). The reaction was reported by two independent research
groups of Sharpless and Meldal in 2002 [180].
The [3 þ 2] cycloaddition between azides and alkynes to form
1,2,3-triazoles was described previously in 1963 by Huisgen
(Fig. 18), but the reaction required elevated temperatures and twoHuisgen [3+2] cycloaddition
CuAAC
SPAAC
Fig. 18. Various azide-alkyne [3 þ 2] cycloadditions; the Huisgen [3 þ 2] cycloaddition,
the CuAAC and the SPAAC.regioisomers (the 1,4- and 1,5-substituted triazole) were formed
[181]. The introduction of a Cu-catalyst enabled a regiospeciﬁc re-
action yielding only in the 1,4-regioisomer. Moreover, the Cu-
catalyst also allowed performing the reaction at lower tempera-
tures [180,182]. On the other hand, the necessity of toxic Cu(I)
prevents the use of the CuAAC for in vivo chemistry as Cu-ions can
interact or chelate with biomolecules [183].
In order to circumvent the use of a metal catalyst, considerable
efforts were directed towards ﬁnding a catalyst-free variant of the
reaction. It was found that Cu was not necessary if the alkyne
moiety could be activated by electron withdrawing groups (EWG).
In this case, cycloadditions between ethyl 5-azidovalerate and both
internal and terminal alkynes, e.g. methyl propiolate, ethyl but-2-
ynoate and propargyl benzenesulfonate, could occur at room
temperature and only the 1,4-regioisomer was formed [184].
However, these types of alkynes are not appropriate for in vivo
chemistry, since they can also easily participate in Michael addi-
tions with nucleophiles [176]. In an attempt to increase reactivity of
the alkynes, Bertozzi and co-workers started to study how the re-
actionwas inﬂuenced by ring strain, an approach already pioneered
by Wittig and Krebs with the smallest stable carbocyclic alkyne,
cyclooctyne. This work resulted in a new bioorthogonal reaction;
the SPAAC (Fig. 18) [176,185]. Here, the release of ring strain in the
cyclooctyne upon reaction with the azide drives the reaction. No
toxicity was observed when the authors applied the reaction in
living cells (Fig. 18) [186]. The SPAAC was later successfully used for
in vivo approaches in both zebraﬁsh and mice [187,188].
The relationship between structural changes of the cyclooctyne
and reaction kinetics for the SPAAC has been studied and an EWG,
such as ﬂuorine adjacent to the alkyne moiety is favorable for the
rate of the reaction. Rate constants of approximately 0.1M1 s1
can be reached [186,189]. In addition, cyclooctynes with fused ring
system, e.g. dibenzocyclooctynes (DIBO), aza-dibenzocyclooctynes
(DIBAC) and biarylazacyclooctynone (BARAC) show high rate con-
stants, 0.17M1 s1 (MeOH), 0.36M1 s1 (D2O) and 0.96M1 s1
(MeCN), respectively [190e192]. However, the latter is reported to
undergo spontaneous intramolecular rearrangement, which limits
its use for in vivo applications [193].7
3.3.2.1.1. Preclinical pretargeting applications. To our knowledge,
there are until now only three published studies, which use the
SPAAC for pretargeting approaches in respect to nuclear imaging or
radiotherapy [61,194]. For imaging purposes, a pretargeting PET
approach was reported by Lee et al. in 2013, when mesoporous
silica nanoparticles (NPs) were used to image U87 malignant gli-
oma tumors in mice. PEG-linkers were attached to the NPs to in-
crease biocompatibility and the size of the particles was set to be
approx. 100e150 nm, a range in which NPs are reported to show
EPR-mediated tumor targeting. Further modiﬁcations of the NPs
were conducted in order to introduce the reactive tag (DIBAC) for
the SPAAC. The PEG-linkers contained amine-functionalized end-
groups that were coupled to NHS-functionalized DIBACs. After
assessing tumor accumulation of the NPs by optical imaging, pre-
targeted imaging was performed with [18F]ﬂuoropentaethylene
glycolic azide 4 as a secondary imaging agent (Fig. 19A). The time
interval between administration of DIBAC-NPs and 18F-labeled
azide, respectively was set to 24 h [61]. A longer period of time was
not selected because the used cyclooctyne moieties tend to un-
dergo side reactions with biological nucleophiles, such as free thiol
groups of cysteines during long-term in vivo exposure [195].
DIBAC-NPs (100 mg, 12 nmol of DIBAC) were injected i.v. into mice7 It should also be stated that the SPAAC (~1M1 s1) does not have as good
reaction kinetics as the CuAAC (10e100M1 s1) [Rossin, R. et al., Curr Opin Chem
Biol, 2014, 21: 161-9].
Fig. 19. (A) Pretargeted PET imaging with DIBAC-NPs and [18F]ﬂuoropentaethylene glycolic azide 4. (B) PET/CT imaging of mice injected with DIBAC-NPs (250 mg) with a 24 h time
interval before administration of secondary imaging agent, [18F]ﬂuoropentaethylene glycolic azide 4. (C) PET/CT imaging of mice injected with only [18F]ﬂuoropentaethylene glycolic
azide 4. Abbreviations of organs: T¼ tumor; K¼ kidney. Figure modiﬁed from Ref. [105].
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Am of 42 GBq/mmol). Only a minor accumulation of radioactivity at
the tumor-site was observed (1.1% ID/g). Nonetheless, increasing
the dose of the DIBAC-NPs (250 mg, 30 nmol of DIBAC) resulted in a
higher tumor uptake (1.4% ID/g). Speciﬁc tumor binding was veri-
ﬁed by comparing the biodistribution of 18F-labeled azide 4 in non-
pretreated mice, in which no considerable accumulation of radio-
activity in the tumors was observed (Fig. 19B and C) [105].
This study by Lee et al. was the ﬁrst successful in vivo demon-
stration of the SPAAC in pretargeted nuclear imaging. Interestingly,
in the same year van den Bosch et al. also evaluated the feasibility of
the SPAAC in vivo, more speciﬁcally in the blood stream of mice. In
this study a mAb targeting vector (rituximab) functionalized with
azides was used in pair with different radiolabeled cyclooctynes as
secondary imaging agents.8 The cycloaddition was demonstrated
in vitro in PBS, yet it was unsuccessful in vivo. Based on these re-
sults, and in contrast to the results from Lee et al., van den Bosch
and colleagues made the conclusion that the SPAAC is not appro-
priate for pretargeted nuclear imaging because of the low con-
centrations of both the secondary imaging agent as well as the tags
attached to the targeting vector. The limited reaction kinetics of the8 The applied approach is vice versa compared to the SPAAC used by Lee and
colleagues.SPAAC and the serum interaction of the secondary imaging agent
was used as an explanation for the observed results [194].
A possible explanation for the conﬂicting conclusions made
could be the number of accessible reactive tags in each study.
Indeed, a similar dose of reactive tags was administered in both
studies. However, the number of accessible tags will most likely
differ since different primary targeting agents with different
pharmacokinetics were used as well as a different experimental
set-up [103]. Van den Bosch et al. used the SPAAC in order to
perform in vivo click chemistry in the blood stream at relatively low
concentration of reactive tags (18.5 mM). The secondary imaging
agent was administered shortly (5min) after the injection of the
azide-functionalized mAb [194]. In contrast, Lee et al. used the
SPAAC to proceed at the tumor-site for pretargeted imaging 24 h
after the administration of the functionalized NPs. As a conse-
quence, the local concentration of reactive tags is probably higher
in this approach. Unfortunately, the local tag concentration has not
been determined by Lee and colleagues [105], therefore any con-
clusions are speculative. On the other hand, the NP dose-dependent
tumor uptake reported by Lee et al. supports the theory that higher
local concentration of reactive tags increases the probability for the
SPAAC to occur in an in vivo setting [103]. However, a thorough
investigation of this hypothesis has not been reported so far.
In 2018, the SPAAC was successfully used for another pre-
targeting strategy using a slightly different approach. A DIBO-
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nent and a multi-azide functionalized dendrimer radiolabeled with
yttrium-90 was used. The mAb was injected 24 h prior to the
radiolabeled dendrimer. Interestingly, the second order rate con-
stants for each single azide within the dendrimer
(k2¼ 232M1 s1) was increasedmore than 100 times compared to
its small molecule analog (k2¼ 2.1M1 s1). This rate constant in-
crease as well as the increased concentration of azides could be
responsible for the possibility to use the SPAAC for pretargeting
approaches [196].3.3.2.2. The tetrazine ligation. Another and even more powerful
bioorthogonal reaction is the tetrazine ligation [177,197e199].
Compared to the SPAAC, the tetrazine ligation shows superior re-
action kinetics, where impressive rate constants up to
1067M1 s1 have been reported [200e202].
In addition, the high speciﬁcity, the small molecule character
and the orthogonality towards biological moieties make this liga-
tion highly interesting for pretargeting approaches in vivo. Mech-
anistically, the tetrazine ligation consists of two steps. The ﬁrst step
is an enthalpy driven inverse electron-demand Diels-Alder [4 þ 2]
cycloaddition (IEDDA) between a 1,2,4,5-tetrazine (Tz) and a
dienophile (either alkene or alkyne). This cycloaddition is followed
by an entropy driven retro Diels-Alder reaction (retro DA), in which
nitrogen gas is eliminated and a dihydropyridazine or pyridazine
adduct is formed (Fig. 20A) [177].
In contrast to the standard Diels-Alder reaction (DA) reaction,
which is a [4þ 2] cycloaddition between an electron rich diene and
an electron poor dienophile [203], the IEDDA has diene/dienophileFig. 20. (A) The tetrazine ligation, consisting of an inverse electron-demand Diels-Alder [4
second step consisting of a retro Diels-Alder reaction (retro-DA). (B) Frontier molecular orb
electron donating group; EWG, electron withdrawing group. HOMO ¼ Highest Occupied Mpairs with opposite electronic character, i.e. an electron poor diene,
the Tz, and an electron rich dienophile. In the IEDDA, the Tz and the
dienophile interact in a suprafacial fashion (Fig. 20A). The interac-
tion occurs between the four p-electrons of the Tz and the two p-
electrons of the dienophile. In accordance with frontier molecular
orbital theory, the IEDDA is governed by the energy gap between
the HOMODienophile (Highest Occupied Molecular Orbital) and the
LUMODiene (Lowest Unoccupied Molecular Orbital). The electron
poverty of the diene results in a LUMO at a lower energy level
compared to the diene in a normal DA. At the same time the
electron richness of the dienophile places its HOMO at a higher
energy level. As a consequence, in an IEDDA it is the HOMO of the
dienophile that interacts with the LUMO of the diene (Fig. 20B).
After the IEDDA, a strained bicyclic ring system is formed, which is
rapidly deconstructed by a retro DA reaction driven by the release
of nitrogen gas to form, depending on the dienophile used, either
pyridazine (alkyne as dienophile) or 4,5-dihydropyridazine (alkene
as dienophile) are formed. The latter is isomerized to 1,4-
dihydropyridazines (two possible isomers) or oxidized to pyr-
idazine (Fig. 20A) [201,204,205].
3.3.2.2.1. Inﬂuencing the reaction kinetics of the tetrazine ligation.
The rate determining step of the tetrazine ligation is the actual
IEDDA. By inﬂuencing the energy gap between the HOMODienophile
and the LUMODiene, the reaction kinetics for the ligation can be
altered. The smaller the energy gap is the faster the IEDDA will be.
Thus, when the Tz-scaffold is substituted with EWG, the LUMODiene
will be at a lower energy level, which results in a more reactive
compound and faster reaction rates in the cycloaddition with a
dienophile [204e207]. However, with increasing reactivity towardsþ 2] cycloaddition (IEDDA) between a tetrazine (Tz) and a dienophile, followed by a
ital theory for a normal Diels-Alder reaction (DA) and the IEDDA. Abbreviations: EDG,
olecular Orbital, LUMO (Lowest Unoccupied Molecular Orbital).
Fig. 21. General reactivity inﬂuence among TCOs and Tz-derivatives.
9 It is worthwhile to mention that a variety of substituted Tz-derivatives can also
be produced via nucleophilic aromatic substitution (SNAr) starting from an
appropriate Tz-scaffold with a leaving group (Scheme 1D and E) [Boger, D.L. et al. J
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in vivo. The most reactive Tz-derivatives e.g. those bearing tri-
ﬂuoromethyl groups are too reactive to be used in vivo, whereas
scaffolds bearing pyridyl substituents in the 3,6 positions, have
shown high rate constants and still applicability for pretargeting
strategies in vivo [100,201,208]. In addition to the electronic char-
acter, steric effects also play an important role, both for the Tz and
the dienophile. For instance, a mono-substituted Tz is highly
reactive due to less steric hindrance in the interaction with the
dienophile [209].
For the dienophile, electron donating groups (EDGs) raises both
its HOMO and LUMO to a higher energy level, whereas EWGs will
place them on a lower energy level, which tend to alter the reaction
to a normal DA instead [198]. Nonetheless, dienophile ring strain
appears to have the greatest inﬂuence on the reactivity and the
most reactive and most frequently used dienophiles are based on
trans-cyclooctenes (TCO) [177,200,210]. For instance, TCOs with a
cis-ring fusion with cyclopropane (s-TCO, Fig. 21) are highly reac-
tive, since the eight-membered ring is forced into a strained half-
chair conformation [210]. A rate constant of 2.8 106M1 s1 (in
PBS) determined with a bis-pyridyl Tz (radiolabeled with lutetium-
177) has been reported for s-TCO. Unfortunately, derivatives based
on this type of TCOs tend to isomerize to its less stable cis-isomer
in vivo over time, which limits their applications for pretargeting
approaches [97,211]. In response to this, Fox and co-workers
developed a TCO fused with a dioxolane ring (d-TCO, Fig. 21),
which showed better tolerance to physiological conditions and still
impressive reaction kinetics with measured rate constants up to
105M1 s1 with bis-pyridyl Tz-derivatives [200]. A general over-
view of structure e reactivity relationship among Tz-derivatives
and various dienophiles is shown in Fig. 21.
3.3.2.2.2. Synthesis of tetrazines. The Tz-framework can be
traced back till the end of the 19th century, when Pinner published
a synthetic route starting from imidoesters and hydrazine. A sub-
sequent oxidation of the dihydrotetrazine intermediate ﬁnallyresulted in the actual Tz-scaffold (Scheme 1A) [212]. Even though
the Pinner reaction is still used, the chemistry involving Tz-
frameworks has over the years been explored and additional syn-
thetic procedures to access these heterocycles have been reported.
For instance, a modiﬁed Pinner reaction or a so called “Pinner-like”
reaction, in which two nitriles are condensed in the presence of
hydrazine, serves as a good alternative to the original procedure
(Scheme 1B). Metal- and sulfur mediated versions of this reaction
have been reported [213,214]. For the metal-mediated approach,
Zn(OTf)2 and Ni(OTf)2 have been used. So far, the mechanism of
action of the metal ion is uncertain. It has been suggested that the
metal ion promotes the reaction by either coordinating to the nitrile
and then facilitating the nucleophilic attack by hydrazine, or by
coordinating both the nitrile and hydrazine to form a reactive
amidrazone intermediate [213]. The proposed mechanism for the
sulfur-mediated version involves the formation of a more reactive
nucleophile, NH2NHSH, that later reacts with the nitriles to form an
intermediate, which in turn eliminates H2S while forming dihy-
drotetrazine [214]. Although, the aforementioned methods have
been applied successfully to synthesize both symmetrical and
asymmetrical Tz-derivatives, there is still a challenge with asym-
metrical Tz-derivatives due to the statistical formation of products
using the above described procedures. As such, a sequential syn-
thetic approach was developed. In this approach, 1,2-
dichloromethylene hydrazines are ﬁrst synthesized, then
condensedwith hydrazine, and ﬁnally oxidized (Scheme 1C) [215].9
However, the synthetic procedure is not working for all kind of
tetrazines. In summary, none of the aforementioned synthetic
procedures is preferred over the other. Which procedure to choose
depends on the nature of the substituents on the Tz-scaffold.Org Chem, 1998. 63: 6329e6337].
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methods form ﬁrst a dihydrotetrazine intermediate, which has to
be oxidized in order to form the Tz entity. Most commonly
employed reagents for the oxidation are 2,3-dichloro-5,6-dicyano-
1,4-benzoquinone, (diacetoxyiodo)benzene, chromium trioxide
and nitrous reagents (e.g. sodium nitrite and isoamylnitrite)
[177,205,216e219]. The latter is not good for Tz-scaffolds bearing
sensitive functionalities, such as aromatic amines [177,217].
3.3.2.2.3. Synthesis of trans-cyclooctenes. The most frequently
applied dienophiles in the tetrazine ligation and the most reactive
ones are based onTCO. Fox and colleagues showed in 2008 that TCO
can easily be prepared on a large scale from commercially available
cis-cyclooctene via photoisomerization and continuously passing
the mixture through a AgNO3/SiO2 column (Scheme 2A and C). The
trans-isomer is retained on the column, whereas the cis-isomer is
not. Instead it is eluted back to the reaction ﬂask for further pho-
toisomerization. Once full conversion to the trans-isomer isachieved, the column is removed and the AgNO3/SiO2 is stirred in
NH4OH. Afterwards, the AgNO3/SiO2 - NH4OH suspension is
extracted to isolate the TCO [220]. The more reactive d-TCO 5 can
also be formed on a gram scale, by ﬁrst reacting (1R,2S)cyclooct-5-
ene-1,2-diol 6 with a glycolaldehyde dimer and subsequent pho-
toisomerization (Scheme 2B) [200].
3.3.2.2.4. From initial introduction of the tetrazine ligation as a
bioorthogonal reaction to early applications and radiolabeling - a
brief historical summary.. The tetrazine ligationwas introduced as a
potential bioorthogonal reaction almost simultaneously by two
independent groups in 2008 [177,221]. Already in one of the
initially published papers in 2008, the tetrazine ligation was uti-
lized for pretargeted imaging (Fig. 22A). Selective ﬂuorescent im-
aging of SKBR3 human breast cancer cells succeeded with a
norbornene-functionalized trastuzumab mAb targeting the HER2
receptor [222] and a near-IR (near-IR) Tz imaging agent, namely Tz-
VT680 7. Norbornene and Tz-frameworks undergo ligations with
A)
B)
C)
6 5
Scheme 2. (A) Synthetic procedure towards 5-hydroxyl-TCO. (B) Synthetic procedure towards d-TCO. (C) Schematic overview of the photoisomerization set-up. Figure modiﬁed
from Ref. [220].
A) B) C) D)
E) F)
77
Fig. 22. (A) Pretargeted approach using norborene- and rhodamine-functionalized trastuzumab and a Tz imaging agent bearing a near-IR probe (VT680). (B) Rhodamine channel (C)
Near-IR channel (D) Merged image of both rhodamine and near-IR channel (E) Control experiment, in which trastuzumab functionalized with only rhodamine and no norberene was
used (rhodamine channel is shown) (F) Control experiment, in which trastuzumab functionalized with only rhodamine and no norberene was used (near-IR channel is shown).
Figure modiﬁed from Ref. [221].
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Imaging showed perfect alignment between traditional ﬂuorescent
imaging of trastuzumab and the near-IR pretargeting approach
(Fig. 22BeF) [221]. These promising results rapidly attracted in-
terest in the ﬁeld of radiopharmaceutical science. Only two years
later, in 2010, the ﬁrst successful pretargeted nuclear imaging with
SPECT was reported by Rossin et al. [100]. This pioneering study
paved the way for the design and development of various Tz/
dienophile pairs for the use in pretargeted diagnostic imaging, but
also for pretargeted radiotherapy.
3.3.2.2.5. Pretargeting strategies. In theory, either a Tz-
derivative or a TCO moiety can be used to functionalize the tar-
geting vector. The most frequently applied method in nuclear im-
aging is to functionalize the targeting vector with TCO and
radiolabel the Tz counterpart. A reason for this is the differences in
the in vivo stability of both the Tz and the TCO. The logical approach
would be to functionalize the longer circulating primary agent with
themost stable of the reactive pairs and use the least stable reactive
pair for the faster clearing secondary agent. The stability and
reactivity of TCO-functionalized primary targeting agents have
been extensively explored. For instance, Rossin et al. have shown
that the metabolically unstable TCO moiety [223] can be stabilized
when attaching it in close proximity (shorter linkers) to the pri-
mary targeting vector. Biological half-lives of up to 6 days were
reached using this approach. In contrast free TCO inmouse serum is
completely isomerized to cis-cyclooctenewithin 8 h. The cis-isomer
is not suitable for in vivo pretargeting strategies. Rossin et al. could
show that the extended biological half-life in the ﬁrst example
comes as a result of shielding the TCO-moiety with the nano-sized
targeting agent from Cu-containing enzymes [97]. This shieldingprevents cis-trans-isomerization that in turn is mediated by Cu-
containing enzymes. A similar approach to prolong the biological
half-life of Tz-frameworks has so far not been described. Further-
more, highly reactive Tz-derivatives are for example not stable
towards cysteine residues. In this respect, we will focus our dis-
cussion solely on pretargeting systems that use TCO-functionalized
primary targeting agents and Tz-derivatives as secondary imaging
agents. Although it should be mentioned that a TCO has been
radiolabeled with ﬂuorine-18 [224] and also used in pretargeting
strategies [223].
3.3.2.2.6. Preclinical applications
1) Proof-of-principle studies with SPECT
The ﬁrst successful application of the tetrazine ligation in pre-
targeted nuclear imaging was published in 2010 by Rossin et al. In
this work, a DOTA-functionalized bis-pyridyl Tz labeled with
indium-111 ([111In]In-DOTA-PEG11-Tz 1) was used as the secondary
imaging agent. This probe was applied in combination with a non-
internalizing TCO-modiﬁed mAb CC49 (CC49-TCO), targeting the
tumor-associated glycoprotein 72 (TAG-72) that is expressed by
human colon LS174T cancer cells. The CC49-TCO (100 mg, 7.4 TCOs/
mAb) was injected i.v. into mice bearing LS174T tumors, and after a
lag time of 24 h the 111In-labeled Tz (21 mg, 3.4 equiv to TCO, 20e50
MBq) was administered. SPECT/CT imaging showed accumulation
in the tumor 3 h after injection and a tumor-to-muscle ratio of 13:1
(Fig. 23A). Non-target tissues, such as liver and blood showed low
levels of radioactivity. As negative controls, micewere injectedwith
either CC49 without TCO or TCO-modiﬁed rituximab. The latter
does not target TAG-72. In both cases, no radioactivity accumulated
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Fig. 23. Pretargeted tumor imaging with various pretargeting systems. (A) SPECT/CT image for CC49-TCO/[111In]In-DOTA-PEG11-Tz 1 system. (B) PET images and PET/CT image for
huA33-TCO/[64Cu]Cu-SarAr-Tz 10 system. (C) PET images for Cetuximab-TCO/[18F]FDR-Tz 18 system (top) and Trastuzumab-TCO/[18F]FDR-Tz 18 system (bottom). (D) PET images for
5B1-TCO/Al[18F]F-NOTA-Tz 12 system. (E) PET images for huA33-TCO/[18F]PMT10 19 system (top) and control experiments with mAb without TCOs and [18F]PMT10 19 (bottom). (F)
PET images for 5B1-TCO with Al[18F]F-NODA-Tz 14 and [68Ga]Ga-NODA-Tz 13 systems, respectively and the huA33-TCO/[68Ga]Ga-NODA-Tz 13 system. The tumors are indicated by
an arrow with or without the letter T. Additional abbreviations of organs: In¼ intestines; L¼ liver. Figures modiﬁed from Refs. [100,106,208,221,225,226].
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These promising results encouraged Rossin and colleagues to
further optimize the approach [97]. One challenge within any
pretargeting strategy is the stability of the reactive tag, i.e. in this
case the TCO on the targeting vector. In the pioneering work, the
TCO attached to the mAb CC49 was slowly deactivated by cis-trans-
isomerizationwith a biological half-life of approx. 3 days. However,
a longer biological half-life would allow for longer circulation time
of the targeting vector and consequently, for higher target accu-
mulation and improved imaging contrast. In light of that, Rossin
et al. investigated if the linker length between CC49 and the TCO
was inﬂuencing the in vivo stability of the TCO. Shorter linker
length improved the stability dramatically (see also section 3.2.6:
Pretargeting strategies) [97,227]. Another important aspect of
pretargeted imaging is the reactivity of the pretargeting pairs. In
respect to this, Rossin and colleagues developed a TCO with
improved reaction kinetics in the ligation with Tz-derivatives.
Substitution of TCO in the axial position rather than the equato-
rial positionwith bulky linkers showed a 10-fold reactivity increase.
These two improvements were implemented in the mAb-TCO10 The optimized mAb consisted of 10.6 TCOs/mAb. The original consisted of 7.4
TCOs/mAb [Rossin, R. et al., J Nucl Med, 2013, 54: 1989-95] [Rossin, R. et al., Angew
Chem Int Ed Engl, 2010, 49: 3375-8].design. The optimized mAb10 was used in pretargeted imaging
experiments with 111In-labeled Tz 1 (Table 3). In this study, an
increased lag time from 24 h to 72 hwas used to reduce the amount
of circulating mAbs compared to the original study, resulting in
higher target-to-non-target ratios [97,100].
In order to further increase imaging contrast, a clearing agent
was applied in the CC49-TCO/[111In]In-DOTA-PEG11-Tz pretargeting
strategy. In these experiments, a galactose-albumin construct was
functionalized with Tz-derivatives (9e13 Tz-derivatives/albumin
galactose) and used to clear free circulating TCO-functionalized
mAbs from the blood to the liver [97]. This type of clearing agent
has previously shown promise in pretargeting experiments based
on the (strept)avidin-biotin interaction [228]. The clearing agent
was administered to mice pretreated with CC49-TCO 30 h earlier.
After 3 h111In-labeled Tz 1 (Table 3) was injected. This set-up
resulted in more than a 100-fold higher imaging contrast
compared to the results from the original study (Fig. 4C) [97].
2) Initial PET studies
After the landmark study by Rossin et al., Lewis et al. extended
the pretargeted imaging approach based on the tetrazine ligation
from SPECT to PET. His research group used a NOTA-functionalized
Tz and labeled it with the PET radionuclide copper-64. This Tz was
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Various reported Tz-derivatives for pretargeting applications.
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E.J.L. Steen et al. / Biomaterials 179 (2018) 209e245 231applied in the pretargeted imaging of SW1222 human colorectal
carcinoma xenografts using a TCO-modiﬁed mAb A33 (huA33-TCO,
5 TCOs/mAb) [229]. HuA33 is reported to be persistent towards
internalization with a turnover half-life greater than 2 days in vitro
[231]. After assessing the tumor accumulation time for the mAb,
pretargeting experiments were performed, in which huA33-TCO
(100 mg) was administered 24 h prior to i.v. injection of 64Cu-
labeled Tz 8 (Table 3) (10.2e12.0 MBq, 1.2e1.4 mg, As¼ 8.9± 1.2
MBq/mg). Radioactivity accumulation in the tumorwas already seen
after 1 h with a value of approx. 4.1% ID/g. Increasing the dose of
huA33-TCO to 300 mg resulted in a similar tumor uptake, but higher
radioactivity levels in the blood. The latter is likely a result of tet-
razine ligation occurring in the blood with the remaining circu-
lating mAb. Even though the pretargeted imaging approach
resulted in lower tumor uptake compared to the traditional imag-
ing with directly 64Cu- or 89Zr-labeled huA33, a higher tumor-to-
muscle ratio, as well as a lower absorbed radiation burden to
non-target tissues were observed in the pretargeting experiments
[229].
Unfortunately, the 64Cu-labeled Tz applied in this study cleared
through the intestines, which is not optimal when imaging colon
cancer. In an attempt to alter the excretion pathway, two new Tz-
derivatives were designed with the overall aim to increase polar-
ity and obtain renal clearance. In comparison to the lead com-
pound, the ﬁrst Tz was designed with a long PEG-linker (7 units)incorporated between the Tz-scaffold and the NOTA chelator
([64Cu]Cu-NOTA-PEG7-Tz 9). For the second derivative the NOTA
chelator was replaced by a sarcophagine-based chelator (SarAr)
([64Cu]Cu-SarAr-Tz 10, Table 3), which changed the overall charge
of the radioligand from 1 to þ2. Results from biodistribution
studies of both Tz-derivatives showed that [64Cu]Cu-SarAr-Tz 10
(Table 3) was the better tracer, with a superior pharmacokinetic
proﬁle and pure renal clearance. [64Cu]Cu-NOTA-PEG7-Tz 9
(Table 3) exhibited clearance via the gastrointestinal and urinary
tracts. The reason for the different clearance pathways was sug-
gested to be mainly due to the overall positive net charge of [64Cu]
Cu-SarAr-Tz 10 (Table 3) [225]. Despite different pharmacokinetic
proﬁles, both [64Cu]Cu-SarAr-Tz 10 (Table 3) and [64Cu]Cu-NOTA-
PEG7-Tz 9 (Table 3) were successfully applied to pretargeting ex-
periments, in which huA33-TCO (100 mg, 0.66 nmol) was adminis-
tered 24 h before injection of the Tz-derivatives. Additional non-
radioactive Tz was added to the injection solution to adjust the
molar ratio to 1:1 with the amount of injected huA33. PET imaging
was carried out at time points ranging from 1 to 24 h p.i. of Tz. For
[64Cu]Cu-SarAr-Tz 10 (Table 3) the tumor uptake increased over
time (from 5.63± 0.67% ID/g 1 h p.i. to 7.38± 2.02% ID/g 24 h p.i.),
whereas for [64Cu]Cu-NOTA-PEG7-Tz 9 (Table 3) the accumulation
of radioactivity was roughly the same for all time points
(4.07± 0.25% ID/g 1 h p.i. and 3.94± 0.92% ID/g 24 h p.i.). Further
experiments were performed with [64Cu]Cu-SarAr-Tz 10 (Table 3)
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respectively. However, the highest tumor uptake was observed
with the initially used 24 h lag time. This could have been expected
since TCOs tend to be deactivated over time by cis-trans-isomeri-
zation [225].
3) The ﬁrst pretargeted imaging study using a short-lived
radionuclide
As a next step, it was attempted to replace the medium-lived
copper-64 with shorter-lived radionuclides in order to exploit the
full potential of pretargeted imaging, i.e. maximizing imaging
contrast while reducing radiation exposure to healthy tissue. In
2014, Evans et al. reported the radiolabeling of a Tz with gallium-68
(11) (Table 3) and its evaluation in pretargeted experiments
[110,232]. For the pretargeted imaging studies cetuximab was
modiﬁed with TCOs (17 TCOs/mAb) and used as primary targeting
agent [110]. Mice bearing EGFR expressing A431 tumor xenografts
were pretreated with TCO-modiﬁed cetuximab and 23 h later 68Ga-
labeled Tz 11 (Table 3) (approx. 1.85 MBq) was injected. This
resulted in a tumor uptake of 3.48% ID/mL. Experiments with 3 h
between injection of mAb and 68Ga-labeled Tz 11 (Table 3) were
also performed, but a tumor uptake of only 0.86% ID/mL was
observed using this setup. Both in the biodistribution of directly
radiolabeled mAb and in pretargeting experiments with the Tz,
high liver uptakes were observed, whichmight be a consequence of
the high TCO-loading/mAb.11 Biodistribution studies of [68Ga]GaCl3
and 68Ga-labeled Tz 11 (Table 3) were performed as negative con-
trols to verify speciﬁc tumor uptake in pretargeted imaging ex-
periments [110].
4) PET studies with short-lived, non-radiometal radionuclides
A major drawback with radiometal-based Tz-derivatives is that
they are limited to extracellular targets. Current chelator-based
structures cannot cross cell membranes. In addition, many nano-
materials and mAbs internalize to some degree, which limits or
even in some cases prevents the use of radiometal-labeled Tz-de-
rivatives. In this respect, efforts have been directed towards
developing Tz-scaffolds labeled with carbon-11 and ﬂuorine-18.
These types of compounds would have the potential to be used
for intracellular targets as well. Moreover, carbon-11 and ﬂuorine-
18 possess outstanding nuclear imaging properties that result in a
relatively low radiation burden and good image contrast compared
to standard applied radiometals (Table 1). Carbon-11 easily allows
for test-retest experiments within one day with the same test
subject. Fluorine-18 offers several advantages, e.g. due to its half-
life of 110min it is optimal for clinical routine applications and
commercialization. The half-life also enables multi-step radio-
syntheses12 within business hours and productions as high as 300
GBq. Patient doses are typically 200e400 MBq. Furthermore, the
half-life and the achievable ﬂuorine-18 amount allows for
centralized production with distribution to other facilities. A
transportation range of 200e300 km is certainly possible. However,
labeling Tz-derivatives with carbon-11 or ﬂuorine-18 does not
come without challenges. Whereas, radiometal-labeling normally
proceeds under rather mild conditions, 11C- and 18F-labeling11 The authors claim that the high levels of activity in the liver are characteristic
with the pharmacokinetic proﬁle of mAbs [Evans et al., Chem. Commun., 2014, 50:
9557-60].
12 As a rule of thumb, the production of a PET tracer should not take longer than
4 h and the synthesis should be carried out within three half-lives of the respective
nuclide.require more harsh reaction conditions, which tend to be tedious to
apply on the sensitive Tz-framework. Despite these challenges,
groups have reported various Tz-derivatives labeled with these
radionuclides [106,107,208,216,224,226,230].
Carbon-11
In 2013, the ﬁrst 11C-labeled Tz 15 (Table 3) was reported [216].
Data from studies in pigs demonstrated that Tz 15 (Table 3) is
metabolized rapidly in vivo (26% intact tracer after 10min), but
indication of brain-uptake was observed from PET imaging (sum-
med 6e20min p.i.). No pretargeted evaluation studies were re-
ported [233]. In 2016, Denk et al. reported another 11C-labeled Tz 16
(Table 3). This Tz was evaluated in female BALB/c mice using two
different mesoporous silicon-based NPs modiﬁed with either
standard TCO (116 mmol/g loading) or s-TCO (119 mmol/g loading).
The NPs were labeled via ligation with the 11C-labeled Tz and
thereafter administered. Already 5min p.i. a high uptake in the
lungs (18e25 SUV) could be detected. The reason for more or less
exclusive lung accumulation is most likely due to aggregation of the
NPs (as a result of the high loading of the lipophilic TCOs). None-
theless, these NPs offered a convenient system for evaluating the
new Tz in a pretargeting approach. Hence, for pretargeting exper-
iments, inwhich the NPs were injected 5min before administration
of the 11C-labeled Tz (15.4± 6.0 MBq with a Am of 10± 5.4 GBq/
mmol), the accumulation of activity in the lungs turned out to be
around 1.5 SUV for s-TCO-NPs and approx. 2.5 SUV for TCO-NPs
after 40e60min dynamic PET scanning. The lower uptake for the
s-TCO-NPs might relate to the lower stability of s-TCOs in vivo. For
both types of NPs, a similar molar amount of dienophile was
injected, 59 nmol of s-TCO in a 0.5mg portion of NPs and 58 nmol of
standard TCO in a 0.5mg portion of NPs, respectively [230].
Fluorine-18
Fluorine-18 is considered to be the gold standard among PET
radionuclides for clinical routine studies [234]. As a result, a Tz
labeled with ﬂuorine-18 has attracted great interest among several
research groups.
a) Direct labeling approaches
In 2010, Li et al. tried to radiolabel three different Tz-derivatives
with ﬂuorine-18 applying standard direct 18F-ﬂuorination condi-
tions (Scheme 3A). However, the Tz-framework decomposed and
only traces of the 18F-labeled product could be observed. The use of
nucleophilic bases and the relatively high temperatures applied for
standard 18F-ﬂuorination are not well-tolerated for sensitive Tz-
scaffolds [224]. This was nicely shown by Denk et al., who found
that the tolerance towards standard 18F-ﬂuorination increased with
decreasing reactivity of the Tz-scaffold. Accordingly, direct 18F-la-
beling of a less reactive (compared to the Tz-derivatives used by Li
et al.) bis-alkyl substituted Tz 17 (Table 3) succeeded in a radio-
chemical yield (RCY) of 18% (Scheme 3B) [107].
Biodistribution studies of this 18F-labeled Tz in female BALB/c
mice indicated blood-brain-barrier permeability and renal clear-
ance of the tracer. No accumulation of radioactivity in the bones
was observed, indicating in vivo deﬂuorination did not occur.
Moreover, in vivo stability assessments were performed from
plasma collected 2 h p.i. of the Tz. These showed that the Tz
exhibited a low degree of metabolic degradation, approx. 15%. No
pretargeted imaging experiments were reported, but the ligation to
a TCO was tested in vivo and analysis by radio-TLC showed more
than 90% conversion to the ligation adduct after only 5min. A
promising result for future evaluation in pretargeted imaging
studies [107].
b) Indirect labeling approaches
17
Scheme 3. Direct 18F-ﬂuorination of Tz-derivatives. (A) Early attempts by Li et al. (B) Successful 18F-ﬂuorination of a bis-alkyl Tz.
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Tz derivatives, such as bis-pyridyl or mono-substituted scaffolds
have been reported so far. Instead, indirect 18F-ﬂuorination serves
as a valuable labeling strategy for highly reactive Tz-frameworks. In
such a strategy, a synthon is ﬁrst labeled with ﬂuorine-18 and
thereafter attached to the Tz of interest. Thereby, the Tz is not
exposed to the harsh conditions applied in standard 18F-ﬂuorina-
tion. This type of approach was used in 2016 by Kein€anen et al. In
their work, an aminooxy-functionalized Tz precursor was coupled
to 5-[18F]ﬂuoro-5-deoxyribose ([18F]FDR)13 via oxime coupling. The
product, 18F-labeled Tz 18 (Table 3) was highly hydrophilic and
showed promising reaction kinetics in the ligation with TCO in
plasma (k2¼ 4500M1 s1) [235]. In a follow-up study, this Tz was
evaluated in healthy mice in pretargeted imaging of non-targeting
TCO-NPs. In these experiments, TCO-NPs (0.2mg with 1.42 nmol of
TCO) were injected 15min prior to i.v. injection of the Tz (5.9± 0.5
MBq, 0.17e0.19 nmol, Am¼ 22.2e40.2 GBq/mmol) [106]. The used
non-targeting NPs are known to rapidly clear from the blood
stream in healthy animals via the mononuclear phagocytic system,
e.g. spleen and liver [236]. Therefore, a considerable amount of
radioactivity in the pretargeting studies was observed in the spleen
(10.4± 2.3% ID/g 30min p.i. of Tz) and in the liver (15.8± 4.6% ID/g
30min p.i. of Tz). Untreated mice (without prior injection of TCO-
NPs) showed a Tz accumulation of only 1.9± 0.4% ID/g in the
spleen at the same time point. In addition, high accumulation of
radioactivity was observed in the lungs (13.9± 5.3% ID/g 30min p.i.
of Tz) [106], probably due to aggregation of the NPs. A phenomenon
also observed in previous studies with TCO-NPs [230]. Extending
the lag time to 24 h in the pretargeting experiments did not result
in any tetrazine ligation in vivo, which the authors suggest is due to
the poor stability of the TCOs [106].
Encouraged by these results, 18F-labeled Tz 18 (Table 3) was
evaluated in pretargeting experiments using the TCO-modiﬁed
internalizing mAbs, cetuximab and trastuzumab. As previously13 [18F]FDR can easily be labeled in RCY of 60% (d.c.) [Li et al., Nature protocols,
2014, 9: 138e145].mentioned, cetuximab binds to the EGFR [237] and trastuzumab
targets the HER2-receptor [222]. In order to determine the optimal
imaging time-point for the pretargeting studies, both mAbs were
radiolabeled with zirconium-89. Tumor accumulation occurred
already after 24 h, but good clearance from non-target tissues was
not detected until 72 h p.i. In this respect, 72 h was considered to be
an appropriate period of time for target accumulation in the pre-
targeting imaging experiments. However, earlier time points were
also investigated (24 h and 48 h for cetuximab, and 48 h for tras-
tuzumab). The degree of functionalization was for the cetuximab
6.1± 0.1 TCOs/mAb, whereas the trastuzumab was modiﬁed with
4.9± 0.1 TCOs/mAb [238].
In initial pretargeting studies with high molar activity (Am)
(15e38 GBq/mmol), no signiﬁcant tumor uptake was observed. This
was suggested to be a result of tetrazine ligation occurring with
remaining circulating mAbs and therefore, lower Am was explored.
Here, non-radioactive Tz was added to get a 1:1M ratio with regard
to the molar amount of TCO on the injected mAbs. Two different
groups of mice were used. Group Awas injected with 18F-labeled Tz
diluted with the same molar amount of non-radioactive Tz,
whereas Group B received the non-radioactive Tz (same amount
used as for Group) 5min prior to injection of the 18F-labeled Tz
(same Am used as for Group A). The following conditions were used
in this set-up. Trastuzumab-TCO (20 mg, 0.13 nmol, 0.65 nmol of
TCO) was injected into BT474 tumor-bearing mice and cetuximab-
TCO (75 mg, 0.5 nmol, 3.1 nmol of TCO) was administered into A431
tumor-bearing mice. In general, approx. 16e22MBqwas injected of
the 18F-labeled Tz 18 (Table 3) and the molar ratio was adjusted
with non-radioactive Tz. For experiments with cetuximab 1.39
equiv. of 18F-labeled Tz 18 (Table 3) were used in regard to the
molar amount of injected TCO, whereas for trastuzumab approx.
two equiv. of 18 (Table 3) were used. With this set-up tumor uptake
was observed and PET imaging revealed that the tumor uptake
remained constant over time for both mAbs, while the background
decreased. No signiﬁcant difference was observed for the tumor
uptake between the two groups of mice (A and B) for both targets.
The highest tumor uptake for cetuximab was observed with 72 h
lag time between mAb and 18F-labeled Tz injection (3.54± 0.45%
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mab, there was no observable difference in tumor uptake between
the 48 h and 72 h lag time. PET images 4 h p.i. of Tz for both mAbs is
shown in Fig. 23C. Controls with non-speciﬁc uptake were per-
formed as well [238].
Even though, tumor uptake was observed for both cetuximab
and trastuzumab, it was much lower than the uptake in corre-
sponding conventional imaging experiments with zirconium-89.
The reason for the low levels of radioactivity accumulation in the
tumors for the pretargeting experiments might be explained by the
fact that a non-internalizing Tzwas used. It is likely that 18 (Table 3)
can only react with the small number of mAbs that have not yet
internalized [238]. Since, internalizing mAbs are an important class
of vectors for diagnosis and therapy, the development of 18F-labeled
Tz-derivaties, that are able to cross cell membranes and can be used
as a pretargeting pair, is still ongoing.
5) Miscellaneous
a) Radiometal-like labeling with Al[18F]F
Another possibility to obtain 18F-labeled Tz-derivatives in an
efﬁcient way, while avoiding basic labeling conditions, is to radio-
label with Al[18F]F. Al3þ forms strong bonds to F, in fact stronger
than to most other metal ions [239]. Al[18F]F-labeling can be per-
formed with chelators such as NOTA, NODA, NODAGA and RESCA
[226,240,241]. One drawback using this chelator labeling strategy is
that the produced secondary imaging agent is most likely limited to
extracellular targets. So far, almost all chelator-based structures
cannot cross cell membranes.
In 2016, Lewis and co-workers reported the ﬁrst Al[18F]F-NOTA-
labeling of a Tz-scaffold 12 Table 3). This Tz was evaluated with a
TCO-modiﬁed mAb, 5B1 (5B1-TCO), that targets the carbohydrate
antigen 19.9 (CA19.9), which is a biomarker for pancreatic ductal
adenocarcinoma. The number of TCOs/mAb was not reported. For
the pretargeted PET studies, 5B1-TCO (1.33 nmol) was adminis-
tered, followed by a lag time of 72 h before an equimolar amount of
Tz 12 (Table 3) (1.33 nmol, 18e20 MBq) was injected. PET/CT im-
aging was carried out at 1 h, 2 h and 4 h p.i., respectively. The tumor
uptake increased over time (Fig. 23D) and at the 4 h time point the
radioactivity levels in the tumor were 6.4% ID/g. The plasma half-
life of the Tz was rather long (71.2± 5.40min), which might be an
explanation to the increasing tumor uptake over time [226].
Alternatively, still circulating 5BI-TCO that react with the radio-
labeled Tz in the blood pool and then accumulate at the tumor-site
might also explain the increasing tumor uptake.
b) The inﬂuence of charge and linker on the pharmacokinetic
proﬁle of Tz-derivatives
The straightforward approach using Al[18F]F to easily access 18F-
labeled Tz-derivatives and the possibility to radiolabel the same
moieties with gallium-68 prompted, Lewis, Zeglis and co-workers
to investigate the relationship between pharmacokinetics and Tz-
structure in terms of different substituents, linkers and chelators
(Fig. 24). In total, four different Tz-scaffolds were used to access 25
different Tz-derivatives radiolabeled with either ﬂuorine-18 or
gallium-68. Properties and parameters such as lipophilicity
(logD7.4), in vivo stability, plasma half-life and biodistribution were
determined. On the basis of these results, 15 Tz-derivatives were
selected for pretargeting experiments. The selected group was
thought to cover a wide range of diversity in structure and physi-
cochemical properties of the compounds. However, attributes such
as clearance (preferably renal) and plasma half-life had majorinﬂuence on the decision. The pretargeted imaging experiments
were performed using the same procedure described earlier, with
5B1-TCO as a primary targeting agent (see section 5. Miscellaneous
e Radiometal-like labeling with Al[18F]F). A few trends in the
relationship between structure and in vivo behavior among all the
Tz-derivatives studied could be identiﬁed. Firstly, the overall net
charge inﬂuenced its clearing pathway. A positive charge reduced
the lipophilicity of the radioligand and induced clearance through
the kidneys, whereas compounds with no charge were mainly
excreted via the liver and intestines. This conclusion arose from the
observation that the only structural difference between [68Ga]Ga-
NODA-Tz 13 (Table 3) and Al[18F]F-NODA-Tz 14 (Table 3) arrived
from the radionuclide used. [68Ga]Ga-NODA-Tz 13 resulted in a
charge of þ1 and Al[18F]F-NODA-Tz 14 (Table 3) in a charge of 0.
Secondly, the choice of linker between the chelator and the Tz-
scaffold had an impact. Amino acid linkers generally reduced the
circulation time in the blood stream, as well as induced predomi-
nant clearance via the hepatic system. Finally, the plasma half-life
of the Tz affected the tumor accumulation and was suggested to
preferably exceed 10min for good tumor accumulation in pre-
targeting experiments [208].
Two promising lead compounds could be identiﬁed in this
study, namely Al[18F]F-NODA-Tz 14 (Table 3) and [68Ga]Ga-NODA-
Tz 13 (Table 3). They showed good stability, sufﬁcient plasma half-
life (17.1min and 15.1min, respectively) and high tumor uptake.
PET images with Al[18F]F-NODA-Tz 14 (Table 3), showed a tumor
uptake of 7.6± 1.8% ID/g 2 h p.i. and imaging after 4 h showed an
uptake of 8.8± 1.7% ID/g (Fig. 23F). The 68Ga-labeled Tz 13 (Table 3)
had a tumor uptake of 6.8± 1.4% ID/g 2 h p.i. and 7.1± 1.8% ID/g 4 h
p.i. (Fig. 23F). The ratios between target and non-target tissues
were promising for both 13 and 14 (Table 3) [208].
Based on ex vivo biodistribution, thewhole-body effective doses
of the pretargeting studies of the two new Tz-derivatives were
compared with the doses of the conventional approach, in which
the mAb was directly labeled with zirconium-89. The conventional
approach resulted in a 70-fold higher radiation dose in healthy
tissues. Finally, the clearance proﬁle of both Tz was compared. The
68Ga-labeled derivative 13 (Table 3) displayed a better clearance
proﬁle for imaging purposes, mainly renal, while Al[18F]F-NODA-Tz
14 (Table 3) showed excretion via the liver and intestines. As a
result of this, only additional studies were performed with [68Ga]
Ga-NODA-Tz 13 (Table 3) in mice with colorectal cancer xenografts
using huA33-TCO as a targeting vector with a 48 h lag time before
administration of Tz. In these experiments, 13 (Table 3) exhibited a
tumor uptake of 7.7± 1.1% ID/g 4 h p.i (Fig. 23F). [208].
c) Polymer-based labeling with ﬂuorine-18 and gallium-68
In 2012, Devaraj et al. reported a Tz-coated polymer ([18F]PMT10
19, (Table 3)), which could be radiolabeled with ﬂuorine-18 and be
used as a secondary imaging agent. The polymer was based on an
amino-dextran (10 kDa) backbone functionalized with one ﬂuoro-
chrome and mono-substituted Tz-derivatives (approximately 2 Tz-
derivatives/polymer). A larger polymer (40 kDa) with a higher de-
gree of functionalization (11 Tz-derivatives/polymer) was also
synthesized, but not used in pretargeting studies. Radiolabeling
was achieved by indirect 18F-ﬂuorination via ligation to (E)-5-(2-
[18F]ﬂuoroethoxy)cyclooct-1-ene in a RCY (decay corrected) of 89%
[242]. Pretargeted imaging experiments with [18F]PMT10 19
(Table 3) were conducted in LS174T human colon cancer bearing
mice using the mAb huA33 as a targeting vector, which was func-
tionalized with TCOs (approx. 3 TCOs/mAb) and a near-IR probe
(VT-680). The huA33-TCO-VT680 (30 mg) was administered 24 h
prior to i.v. injection of [18F]PMT10 19 (Table 3) (30 mg, 5.55 MBq).
PET/CT images 3 h p.i. of the Tz-coated polymer showed
Tetrazine scaffolds Linkers Chelators Radionuclides
Fig. 24. Building blocks for the library of Tz-derivatives used to investigate the relationship between structure and in vivo behavior in pretargeting strategies. Abbreviations: NCS ¼
N-Chlorosuccinimide.
Fig. 25. (A) Pretargeted PET imaging using TCO-NPs injected 24 prior to administration
of [64Cu]Cu-DOTA-Tz 20. (B) Conventional imaging of [64Cu]Cu-TCO-NPs. (C) Ex vivo
biodistribution from pretargeting experiments, the conventional approach (64Cu-
labeled TCO-NPs) and biodistribution of [64Cu]Cu-DOTA-Tz 20. (D) Ratios between
tumor and non-target tissues for all three experiments. Figure modiﬁed from
E.J.L. Steen et al. / Biomaterials 179 (2018) 209e245 235accumulation of radioactivity in the tumor (Fig. 23E). Unfortu-
nately, no values for the tumor uptake were given and no infor-
mation about the distribution of the radioactivity in non-target
tissues was reported. However, negative control experiments were
performed, inwhich mice received mAbwithout any TCOs. In these
controls, no accumulation of radioactivity was observed in the tu-
mor (Fig. 23E) [242].
Two years later, in 2014, Devaraj and coworkers also reported
a68Ga-labeled Tz-coated polymer based on the same amino-
dextran backbone. Since 68Ga-labeling requires chelating chemis-
try, the polymer was functionalized with the chelator DTPA before
amide coupling to an NHS-functionalized Tz. The radiolabeled
polymerwas evaluatedwith a similar pretargeting procedure as the
18F-version, although the huA33-TCO had a higher loading of TCOs
(5.3 TCOs/mAb versus 3 TCOs/mAb in previous set-up). The tumor-
to-muscle ratio was 3.9± 1.8 [243].
3.3.2.2.7. Application to tumor-targeting nanomaterials in cancer.
To date, the only reported pretargeted tumor imaging applying the
tetrazine ligation with other targeting vectors than mAbs is Lin and
co-worker's strategy using supramolecular TCO-functionalized NPs
along with 64Cu-labeled DOTA-Tz 20 (Table 3). The NPs were
formed by self-assembling of a TCO-grafted cyclodextrin-poly-
ethylenimine polymer, a cyclodextrin-polyethylenimine polymer,
an adamantane-grafted polyamidoamine and an adamantane-
grafted polyethylene glycol. For pretargeting studies, the TCO-NPs(100 mg, 1 nmol of TCO) with a size of 100 nm were injected i.v.
intomice bearing U87 glioblastoma tumor xenografts. The TCO-NPs
targeted the tumor via the EPR effect, and after a 24 h lag time 64Cu-
labeled Tz 20 (Table 3) (10 nmol of Tz, 11.0 MBq) was administered.
PET/CT images 24 h p.i. of the Tz showed accumulation of radio-
activity in the tumor (Fig. 25A) and the ex vivo biodistribution
revealed a tumor uptake value of 16% ID/g (Fig. 22C). For non-target
tissues (Fig. 25C and D), a high uptake in the liver (17% ID/g) was
observed. Control experiments, including conventional imaging of
the 64Cu-labeled TCO-NPs showed the same result; high liver up-
take (Fig. 25B, C and D). In contrast, the biodistribution of the [64Cu]Ref. [104].
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radioactivity in the liver [104]. Since the amount of radioactivity in
the blood was almost the same for all three experiments (pre-
targeting approach, conventional approach and biodistribution of
Tz), a reason for the high liver uptake in the pretargeting experi-
ments might be that the tetrazine ligation occurred with TCO-NPs
accumulated in the liver.
3.3.2.2.8. Concluding remarks e tetrazine ligation. To date, the
tetrazine ligation is the most promising bioorthogonal reaction in
rodents. So far, it has not been applied in clinical studies. Several
promising Tz-based PET tracers have been developed. For instance,
68Ga-labeled Tz 13 (Table 3) reported by Lewis and colleagues has
shown applicability in imaging of pancreatic ductal adenocarci-
noma as well as colorectal cancer in mice. Furthermore, among the
Tz-derivatives radiolabeled with non-radiometals, 18F-labeled Tz 18
(Table 3) seems to be the most promising candidate at the moment.
It is yet to be shown if one of these tracers will be successful in
pretargeted imaging in patients.4. The potential of pretargeting for radiotherapy based on
non-targeted nanomedicines
Radionuclide therapy is a powerful tool in oncology and has
shown promise in treating cancer patients with prostate cancer,
lymphomas, leukaemias, non-Hodgkin's lymphomas or
somatostatin-receptor expressing tumors [244]. It is based on the
use of therapeutic radionuclides (typically emitting b or a-parti-
cles) that are attached to a tumor targeting vector. After accumu-
lation at the target-site, high cytotoxic radiation levels are
delivered, which ultimately kill the cancer cells [245]. One signiﬁ-
cant advantage of radionuclide therapy compared to conventional
chemotherapy is the possibility to determine the optimal dose
before therapy and to monitor therapy efﬁcacy via molecular im-
aging techniques. Therefore, radionuclide therapy results in an
increased precision and may reduce side effects in patients [244].
One highly selective and speciﬁc form of radiotherapy exploits
mAbs as carriers for therapeutic radionuclides. It is called radio-
immunotherapy (RIT) and has especially shown success in lym-
phomas and leukaemias [246]. However, therapeutic dose levels
that can be applied in RIT are limited by the radionuclide dilemma
(Fig. 3). Long-lived radionuclides have to be used to be compatible
with the slow accumulation and excretion process of mAbs.
Consequently, also healthy tissues are irradiated to a great extent,
which is a major concern regarding organs that are sensitive to
radiation, such as the bone marrow and the kidneys [245]. The
same considerations are also valid for NP-based radionuclide
therapies. Since pretargeting strategies circumvents the radionu-
clide dilemma, pretargeted radiotherapy (PRT) can be applied to
increase radiation dose to diseased tissue and to reduce toxicity toTable 4
Selection of potential radionuclides for targeted radiotherapy [248].
Radionuclide Decay Half-lifea Maximum r
131I b- 8.0 d 2.0mm
90Y b- 2.7 d 11.3mm
188Re b- 0.7 d 10.4mm
177Lu b- 6.7 d 1.8mm
67Cu b- 2.6 d 2.1mm
213Bi a 0.8 h 55 - 85 mm
211At a 7.2 h
225Ac a and b (decay chain) 10 d
212Pb a and b (decay chain) 10.6 h see Ref. [248
Notes:
a Half-life is the time required for the activity to decrease to half of the original amou
b Energies of emitted gamma photons that can be used for imaging purposes.healthy tissue [247]. Not many studies applying PRT have been
performed so far. In the following section, different strategies for
PRT will be described and the potential of the tetrazine ligation for
this purpose will be discussed.
4.1. Radionuclides for targeted radiotherapy
As for imaging purposes, there are a set of radionuclides
accessible that can be used for pretargeted radiotherapy (Table 4).
One key nuclear property is the maximum range of the emitted
particle that is used for therapeutic purposes. Several reviews have
been published discussing the therapeutic potential and use of
these radionuclides [248].
4.2. Pretargeted radiotherapy (PRT)
4.2.1. Non-tetrazine ligation-based studies
Encouraged by the outstanding imaging contrast observed for
mAb pretargeted imaging, most PRT strategies have focused on
antibody conjugates. For example, PRT was applied clinically using
an 131I-labeled hapten and a bsAb. The bsAb targeted the carci-
noembryonic antigen in patients with non-medullary thyroid car-
cinoma (non-MTC) or medullary thyroid carcinoma (MTC). During
the study 70% of the lesions were detected and treated, yet some
liver toxicity was observed. After the study tumor stabilization was
present in 9 out of 22 cases [253]. This is only one out of many PRT
studies based on the interaction between bsAb and haptens that
has been published or are in clinical trials. In general, when a
pretargeting radiotherapeutic strategy is applied an increase of the
overall survival rates has been observed [253,254]. However, as
previously mentioned (see section 3.3.2), there are several chal-
lenges with this approach including immunogenic responses,
which exclude very often repeated treatment.
Another approach, which has been applied for PRT is the biotin
e streptavidin interaction. This system has been used in patients
with glioblastoma. Patients were treated with 90Y-labeled biotin as
the therapeutic agent. An important ﬁnding from this study was
that the tumor-to-bone marrow ratio was higher using the pre-
targeting technique compared to the conventional method (63:1 vs
6:1). Nevertheless, the approach also showed immunogenic re-
sponses in mice and humans [228].
A promising radionuclide for PRT is the alpha-emitter astatine-
211. A number of biotin-derivatives have been 211As-labeled. To the
best of our knowledge, these derivatives have only been evaluated
using in vitro pretargeting [255], while, in vivo experiments are
limited to pharmacokinetics studies [256e258]. Up to date, no
clinical PRT studies using the hybridization of complimentary oli-
gonucleotides have been reported in the literature. Proof-of-
concept studies in mice bearing LS174T tumors showed tumorange in water (mm) Gamma-photon energyb (MeV) References
0.364 (81%) and 0.606 (7%) [249]
1.7 (0.01%) [250]
0.155 (15%) [251]
0.208 (11%) [251]
0.185 (49%) [251]
0.440 (26%) [251]
0.079 (21.3%) [251]
0.099 (93%) [251,252]
] see Ref. [248] [252]
nt.
Fig. 26. Average tumor volume for each group of mice during the pretargeted radio-
immunotherapy study. Tumor growth delayed with increasing amounts of [177Lu]Lu-
DOTA-PEG7-Tz 22 when 5B1-TCO was administered compared to the controls.
Figure modiﬁed from Ref. [261].
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rivative resulted in a higher tumor-to-non-tumor ratio, probably
due to the longer half-life and thereby better dose accumulation in
the tumor over time [166,167].
Finally, the SPAAC has also been evaluated in PRT with mAbs. At
low azide:alkyne ratios, the reaction did not hold as a promising
approach for targeted radionuclide therapy (see section 3.3.5)
[194]. However, at higher azide:alkyne ratios the SPAAC could be
applied to pretargeted therapy. In a recent study, the rituximab
mAb targeting the CD20 antigen in lymphoma cells was function-
alized with 10 DBCO groups and applied in PRT [196]. An 90Y-
labeled dendrimer functionalized with 29 azide groups was used as
the therapeutic agent. In this case, in vivo pretargeting was ach-
ieved and a therapeutic effect was observed. Tumor regression was
observed in all mice, with 67% of mice becoming tumor free, while
the rest had tumor sizes below baseline. Here, the success of the
pretargeting approach was attributed to the high degree of azide-
functionalization of the dendrimer (i.e. number of azides pre-
sent), which supposedly increases the rate of the SPAAC.
4.2.2. Tetrazine ligation-based studies
a) Lutetium-177
There have been several attempts to develop Tz-derivatives
labeled with therapeutic radionuclides. For example, a number of
177Lu-labeled Tz-frameworks have been developed and evaluated
in vivo [259]. Noteworthy is the initial study by Rossin et al. where
it was shown that a clearing step can increase the toxic tumor ra-
diation dose compared to a directly labeled strategy [97]. In this
study LS174T-tumor bearing mice were administered CC49-TCO (7
TCOs/mAb) followed by two doses of a galactose-albumin-based
clearing agent (9e13 Tz/clearing agent) given 30 h and 48 h later.
Two hours after the injection of clearing agent, [177Lu]Lu-DOTA-
PEG11-Tz 21 (Table 5) was administered. To compare PRT with RIT, a
second group of mice were treated with the directly labeled
counterpart e [177Lu]Lu-DOTA-CC49. Ex vivo biodistribution was
used to calculate mouse and human dosimetry.
The use of a clearing agent lead to a 2-fold increase in tumor
uptake and a 125-fold enhancement in the tumor-to-blood ratio
compared to the approach without a clearing agent [97,100,194].
Moreover, the tumor uptake was persistent for at least 7 days,
which is an indication of a sufﬁciently stable ligation adduct. This is
an important fact since retention of radioactivity within the target
region is necessary to guarantee the highest therapeutic effect and
meanwhile the lowest level of radiotoxicity possible to healthy
tissues. In contrast, a similar pretargeting approach using the
streptavidin-biotin interaction and the same therapeutic radionu-
clide (177Lu) resulted in a 10-fold decrease in tumor uptake after 7
days [260]. With regard to dosimetry [177Lu]Lu-DOTA-PEG11-Tz 21
(Table 5) showed high accumulation in the kidneys (1.58% ID/g at
3 h p.i.), however, in pretargeting experiments the bone marrow
was estimated to be the dose limiting organ. Based on the limit for
the maximum tolerated dose to the bone marrow, dosimetry cal-
culations suggested that an 8-fold enhancement in tumor radiation
dose should be possible in mice using the pretargeting system
compared to using the conventional approach. In humans, a one to
two order of magnitude reduction in radiation dose to non-targeted
organs can be expected using PRT compared to RIT [100]. Encour-
aged by these results, several 177Lu-labeled Tz-derivatives have
been synthesized and evaluated by the same group in an attempt to
reduce kidney uptake while retaining tumor uptake. Unfortunately,
none of them showed improved properties. Either they resulted in
poor tumor uptake or poor pharmacokinetics [259]. None of these
177Lu-labeled Tz-derivatives have been reported to be evaluated fortherapeutic efﬁcacy.
Another 177Lu-labeled Tz, namely [177Lu]Lu-DOTA-PEG7-Tz 22
(Table 5), was developed and reported in 2017 [261]. Tz 22 (Table 5)
was used in pancreatic BxPC3 tumor bearing mice pretreated with
5B1-TCO to explore if the radioligand could induce a dose-
dependent therapeutic response. Ex vivo biodistribution showed
a tumor uptake of 4.6% ID/g 4 h p.i. and 16.8% ID/g 120 h p.i. No
clearing agent was used in this study. Although 22 was adminis-
tered 72 h after the mAb, the enhanced tumor uptake was likely
due to ligation in the blood followed by tumor uptake of the con-
jugate. Tumor regression or growth delay was observed at higher
doses when compared to controls where saline or [177Lu]Lu-DOTA-
PEG7-Tz 22 (Table 5) was administered without the TCO modiﬁed
mAb (Fig. 26). Dosimetry estimations of the PRIT strategy using 22
(Table 5) supported that the bone marrow was the dose limiting
organ. These estimations also indicated that the maximum toler-
ated dose (MTD) in humans (male, 70 kg) would be reached after a
single administration of approx. 25.9 GBq (MTD 13.6/m2 body size
surface (BSA)). In comparison, conventional RIT studies with 177Lu
are reported to have a MTD between 1.7 and 2.6 GBq/m2 BSA
[262e264].
b) Copper-67
In 2017, Fujiki et al. reported 67Cu-labeling of a DOTA-
functionalized Tz 23 (Table 5) and its ligation to a TCO-
functionalized anti-IGSF4 mAb. The biological afﬁnity of the mAb
remained intact following the ligation, based on ELISA analysis
[265]. No pretargeting experiments were reported.
c) Lead-212
With the introduction of therapeutics such as the 223Ra agent
Xoﬁgo [266] and the prostate cancer agent 212Bi-PSMA-617 [267],
there is an increasing interest in the utility of a-emitting radionu-
clides in targeted therapy. One of the advantages of a-emitters over
b-emitting radionuclides is that they can deliver a much more
toxic radiation dose while traveling a shorter distance. The ratio
between the amount of energy emitted and the distance travelled
in tissue is known as the linear energy transfer (LET). A higher LET
value is advantageous because micrometastases can be targeted
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rounding healthy tissue [268].
The ﬁrst reported Tz designed for a-therapy was labeled with
lead-212 [269]. Lead-212 (t1/2¼10.6 h) is an in vivo generator
emitting alpha-particles within its decay chain. [212Pb]Pb-DOTA-
PEG11-Tz 24 (Table 5) was evaluated inmice bearing LS174T tumors.
TCO-functionalized CC49 and two doses of a clearing agent were
applied before 24 (Table 5) was administered. The study was per-
formed using the same protocol described above for [177Lu]Lu-
DOTA-PEG11-Tz 21 (Table 5). In a control group, mice were given a
TCO-functionalized mAb lacking afﬁnity for the tumor antigen.
Ex vivo biodistribution revealed a tumor uptake of 0.94% ID/g at
3 h p.i., which declined to 0.66% ID/g 24 h p.i. This value is lower
than what was observed for the 111In- and 177Lu-labeled variants of
this Tz [97,100]. The reduced uptake can be attributed to the
instability of the [212Bi]Bi-DOTA complex, which is produced
following [212Pb]Pb-DOTA decay [252]. Nevertheless, therapeutic
efﬁcacywas observed, and the tumor growth ratewas reducedwith
increasing dose of 212Pb-labeled Tz 24 (Table 5) in the CC49-TCO
pretreated mice compared to the mice given either directly
labeled 212Pb-TCMC-CC49 (RIT approach) or in mice pretreated
with TCO-functionalized mAb lacking afﬁnity for the tumorTable 5
Various potential Tz-derivatives for pretargeted radiotherapy.
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10antigen. Mice that were administered with only PBS or just CC49-
TCO did not have any reduction in tumor growth rate. In addition,
a high kidney uptake (2.5% ID/g 3 h p.i.) was observed, which pre-
vents clinical translation of 24 (Table 5).4.3. The use of pretargeting in theranostic approaches
The importance of a strategy for personalized medicine using
passively targeting nanomedicines has been discussed in section
1.3 (see section 1.3, Fig. 2). Radiotherapeutic treatments with
nanomedicines can result in strong radiotoxicity, therefore it is
undoubtedly necessary to distinguish potential responders from
likely non-responders before proceeding with EPR-based treat-
ment forms [271]. The concept of theranostics in nuclear medicine
combines diagnostic imaging and radiotherapy (Fig. 28A), typically
by using “theranostic twins” e matched pairs of diagnostic and
therapeutic radiopharmaceuticals, which differ negligibly from
each other [272]. Ideally, the only difference is the radionuclide
used [273]. The prostate cancer agent PSMA is a prominent example
for which a theranostic approach has been applied. Here, PMSA
radiolabeled with gallium-68, e.g.68Ga-PSMA-11, is used as a PET
radiopharmaceutical for diagnosis, pre-therapeutic dosimetry andReference
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Fig. 28. Two types of theranostic approaches for nanomedicines in nuclear medicine. (A) Conventional approach. (B) Pretargeting approach.
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applied for the actual treatment [274].
In summary, pretargeting strategies can contribute to the design
and application of theranostic nanomedicines in two important
ways. First, the modular design of pretargeting makes it possible to
use the same tagged nanomedicine formulation for both diagnostic
and therapeutic purposes (Fig. 28B). Second, the radiolabeled sec-
ondary agent in a pretargeting theranostic approach can be a fast-
clearing small molecule, which can drastically reduce the radiation
exposure of healthy tissues.5. Comparison of pretargeting systems
The ﬁve pretargeting strategies discussed in this review have all
shown success for use in in vivo imaging. However, more work is
needed in order to achievewidespread use of pretargeting systems.
Overall, the goal of pretargeting is to reach high target-to-non-
target ratios at an earlier time point compared to the conven-
tional approach with direct targeting. A number of criteria have to
be fulﬁlled when choosing the ideal pretargeting strategy for a
particular system. In addition to the factors that have to be
considered for a direct targeting approach (e.g. properties of target
and targeting vector), a pretargeting strategy also has to take into
account the properties of the secondary agent. These criteria
include (but are not limited to): (I) The secondary agent must bind
to the primary agent with high afﬁnity and fast reaction kinetics
even at low concentrations. (II) The reactive pairs must show a high
degree of stability and not be degraded too rapidly in prior to
interacting or reacting with each other. (III) The pretargeting pairsmust interact or react speciﬁcally or selectively, such that there is
no interference with endogenous biomolecules. (IV) Chemical and
biochemical synthetic strategies should be in place so that (i) the
primary targeting agent can be modiﬁed without disrupting its
pharmacokinetic and pharmacodynamic properties, and (ii) the
radioactive secondary agent can be efﬁciently produced in suitable
quantities to perform the study. (V) The pretargeting pair should
yield adequate target-to-non-target ratios in vivo at early time
points, i.e. efﬁcient clearance or deactivation of the primary tar-
geting agent with or without clearing agents and fast clearance of
the secondary agent after reaching maximum uptake at the target-
site.
Throughout the previous sections, speciﬁc examples of pretar-
geted imaging have been discussed and the advantages and dis-
advantages of each have been outlined. The table below highlights
some important evaluation criteria which serve as benchmarks to
compare each pretargeting strategy (Table 6).5.1. Binding of the pretargeting pair
Early pretargeting strategies were based on non-covalent high-
afﬁnity interactions. The recognition between bsAb and haptens
has showed rate constants of 1035M1 s1 [120]. However, the
interaction is reversible, hence this strategy sometimes results in
low tumor uptake [122]. The (strept)avidin-biotin interaction
shows outstanding rate constants in the order of 107M1 s1
(Table 6). In fact, the binding afﬁnity between biotin and (strept)
avidin is so strong (Kd¼ 1015M) that it is often classiﬁed as irre-
versible binding [149]. Irreversible binding for a pretargeting pair is
Table 6
Comparison of pretargeting strategies [103,132,200,259,275e279].
Pretargeting system Rate Constant
(M1 s1)
Temp.
[C]
t½a (1 mM) In vivo stability of
pretargeting pairs
Target-to-non-
target ratiosb
Clinical
studies
Limitations
Bispeciﬁc antibodies and
haptens recognition
103e5 38 6e41min High Low without
clearing agent
Yes  Reversible binding between hapten and
bsAb
 Limited to Ab targeting vectors
 Lower tumor uptake compared to other
methods
 Afﬁnity between hapten and bsAb highly
dependent on radiometal used
(Strept)Avidin- biotin
interaction
107 37 ca. 0.3 sc High Moderate to high Yes  Susceptibility of radiolabeled biotin to
biotinidase degradation
 Immunogenic response to (strept)avadin
 Competition with endogenous biotin
Hybridization of
complementary
oligonucleotides
104 37 ca. 1min High Moderate No  (PNA): Low tumor uptake when
compared to other methods
 Increased complexity to incorporate
clearing agents
 Challenging preparation
 Only demonstrated in rodent models
Strain-promoted azide-
alkyne [3 þ 2]
cycloaddition
101e102 RT 1e9
months
Low Low to moderate No  Only a few successful in vivo applications
reported
 High molar ratio needed between
pretargeting pairs
TCO-tetrazine ligation 103e6 37 0.4 se
2.8min
Moderate High No  Only demonstrated in rodent models so
far
Tetrazine production is synthetically
challenging
Notes:
a Half-lives calculated from the k2, based on 1 mM concentrations for both tag and probe [103,120,275,276].
b Reported levels are based on trends found in the literature of applied systems. All experiments were performed in various solvents at different concentrations and
temperatures.
c Own calculations. Abbreviations: RT¼ room temperature.
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pretargeting system that is based on non-covalent high-afﬁnity
interactions is the hybridization of complementary oligonucleo-
tides. Rate constants in the order of 104M1 s1 have been reported
for this system. So far, no investigations have been addressed if the
reversibility can inﬂuence the accumulation process [103,275]. The
bioorthogonal reactions discussed in this review (SPAAC and the
ligation between tetrazines and TCOs) are irreversible and the
pretargeting pairs form strong covalent bonds between each other.
Rate constants of 101 - 102M1 s1 have been determined for the
SPAAC. The tetrazine ligation has shown even higher values, in the
order of 1037M1 s1 [200,202].
In general terms, the interaction/reaction between pretargeting
pairs usually occurs with pseudo-ﬁrst order kinetics. Because of
this, high rate constants are necessary. This becomes especially
important when considering translation from small animals, such
as rodents, to larger animals and eventually humans. Larger vol-
umes decrease the probability of the interaction/reaction between
the pretargeting pairs to occur. The success of the (strept)avidin-
biotin interaction and the bsAbs-hapten recognition for in vivo
pretargeting in humans indicate that rate constants of
1037M1s1 are suitable for clinical application. Given this, the
rate constants of the SPAAC could be problematic for clinical
translation. Only two successful preclinical studies have been re-
ported using this system [105,196] and in both cases increased
amounts of the strained alkyne or the azide were used for pre-
targeting to occur.
5.2. Immunogenicity
The bsAb-hapten recognition and the (strept)avidin-bitoin
interaction can induce an immunogenic response in humans [
[108,247]. No reports of an immunogenic response induced byhybridization of complementary oligonucleotides or using bio-
orthogonal strategies have been reported.
5.3. In vivo stability of the secondary pretargeting agent
Stability of radiolabeled haptens has been demonstrated for
in vivo pretargeting systems based on the bsAb-hapten recognition
[280]. In contrast, the stability of biotin remains to be suspectable
since biotin may be degradated via biotinases [141]. Oligonucleo-
tides are usually very prone for metabolism. However, oligonucle-
otides that can be applied for pretargeting systems have been
designed for enhanced stability and show in fact sufﬁcient stability
in vivo [151]. Tags for bioorthogonal chemistry used so far have only
limited in vivo stability [200,259,281].
5.4. Concluding remarks
Considering all aforementioned evaluation criteria, we believe
that the combination of fast reaction kinetics, high speciﬁcity, the
small molecule character, synthetic accessibility, reaction irre-
versibility and bioorthogonality of the tetrazine ligation make it the
most attractive system for many pretargeting approaches. Also, in
contrast to other established pretargeting systems, such as the
(strept)avidin-biotin interaction or the bsAb-hapten recognition,
no concerns about immunogenicity have been reported so far. The
reachable rate constants appear to be in the order of what is clinical
relevant. In principle, the pharmacokinetic proﬁle of the applied Tz
can also be tailored using standard medicinal chemistry strategies.
This could potentially be used for the development of cell mem-
brane permeable Tz-derivatives. So far, pretargeted imaging and
radiotherapy (including the tetrazine ligation) is limited to targets
on the cell surface. Cell membrane-permeating ﬂuorescent Tz-
frameworks have already been developed and used to image
E.J.L. Steen et al. / Biomaterials 179 (2018) 209e245 241intracellular targets, but radiopharmaceutical counterparts are
missing [282e288].
Finally, nano-sized targeting vectors such as polymers, lipo-
somes or nanoparticles can be decorated with a high number of
TCOs. A higher TCO-loading facilitates the likelihood of the tetra-
zine ligation to occur. In this respect, the tetrazine ligation appears
to be especially suited to image nanomedicines or to conduct PRIT.
6. Summary and outlook
Strategies for pretargeted imaging and radiotherapy have been
described since the late 1980s. Since then they have attracted
considerable attention in nuclear medicine, drug discovery and
drug development. Several pretargeting strategies have been
developed over the years. The bsAbs and hapten recognition and
the (strept)avidin-biotin interaction have already been applied in
the clinic. Unfortunately, the bsAb-hapten recognition resulted in a
relatively low imaging contrast and caused an immunogenic
response. Likewise, the (strept)avidin-biotin interaction also
resulted in an immunogenic response and because of that, other
pretargeting strategies for in vivo chemistry have been developed.
Lately, the tetrazine ligation has become the most highlighted
approach for pretargeting strategies. In total 66 publications
(PubMed search) have been published within the ﬁeld of radio-
pharmaceutical chemistry since Rossin and colleagues [100] uti-
lized the tetrazine ligation for nuclear imaging in 2010. This
number is expected to continuously increase in the following years,
especially if a clinical proof-of-principle study will emerge as a
result of the great efforts worldwide to translate pretargeted im-
aging based on the tetrazine ligation from preclinical to clinical
studies. The motivations for clinical translation are many. Firstly,
high target accumulation and excellent image contrasts have been
observed. Also, the pharmacokinetics of the secondary imaging
agent, the radiolabeled tetrazine, can easily be altered, which
makes the tetrazine ligation more versatile compared to other
pretargeting strategies with similar reaction kinetics. In addition,
the tetrazine ligation also allows the imaging of currently inac-
cessible targets, e.g. intracellular targets, since smaller and more
lipophilic Tz-derivatives can be synthesized to cross cell mem-
branes. Ultimately, the tetrazine ligation possesses several favor-
able characteristics for a pretargeting strategy to be applied not
only for nuclear imaging and radiotherapy, but also for theranostic
approaches. For the latter, diagnostic and therapeutic radionuclide
pairs can straightforwardly be incorporated to Tz-derivatives and
the same primary targeting vector can be used for both the diag-
nostic Tz and the therapeutic one (Fig. 28).
From a broader perspective, pretargeted imaging, in particular
approaches based on the tetrazine ligation, is perfectly suited to
translate nanomedicinal drug delivery from bench to bedside since
it can circumvent the radionuclide dilemma (section 2.3, Figs. 3 and
4) and thereby facilitate personalized medicine (section 1.3, Fig. 2).
Currently, the research community has focused mainly on mAbs as
primary targeting agents in pretargeted imaging approaches.
However, nanomedicines hold the advantage to be decorated with
higher amounts of reactive tags (i.e. TCOs for the tetrazine ligation).
As a result, the in vivo reaction between the secondary imaging
agent and the targeting agent is more likely to occur. In our opinion
pretargeting approaches will not only be highlighted as a method
for identifying which patients are in fact responders to nano-
medicinal treatment in the close future, but also improve current
endoradiotherapy approaches and facilitate broader clinical use.
Still, extensivework has to be done to ﬁnd an ideal pretargeting set-
up working in the clinic. Even though the tetrazine ligation shows
great promise, it is not fully clariﬁed if the ligation shows suitable
in vivo characteristics to be translated from mice to humans.Another challenge is to develop a suitable Tz for PET imaging,
preferably radiolabeled with ﬂuorine-18 and with the potential to
image intracellular targets. Finally, there are not many reported Tz-
derivatives radiolabeled with therapeutic radionuclides. It still has
to be shown if one of them can be used in the clinic.Acknowledgements
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